A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of SEP-4199 for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression)
Phase: PHASE2
Conditions: Depressive Episode, Bipolar 1 Depression
Sponsor: Sumitomo Pharma America, Inc.

Titlpage
 
 
 
 
SEP-4199 
Clinical Study Protocol SEP380-201 
 
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 
Study of SEP-4199 for the Treatment of Major Depressive 
Episode Associated with Bipolar I Disorder (Bipolar I Depression) 
 
IND No. 138,026 
EudraCT No. 2018-000103-16 
 
Version 2.00 
04 June 2018 
Incorporates Amendment 1.00 
 
 
SUNOVION PHARMACEUTICALS INC. 
84 Waterford Drive 
Marlborough, MA 01752, USA 
(508) 481-6700 
 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
2 
 
04 June 2018 
RESTRICTED DISTRIBUTION OF PROTOCOLS 
This document contains information confidential and/or of proprietary interest to Sumitomo 
Dainippon Pharma Co., Ltd. and/or Sunovion Pharmaceuticals Inc. (including their 
The information cannot be disclosed to any third party or 
predecessors, subsidiaries or affiliates). 
used for any purpose other than the purpose for which it is being submitted without the prior 
written consent of the appropriate Sumitomo Dainippon Pharma company. 
This information is being provided to you for the purpose of conducting a clinical study for 
Sunovion Pharmaceuticals Inc. You may disclose the contents of this protocol to the study 
personnel under your supervision and to your Institutional Review Board or Independent Ethics 
Committee for the above purpose. You may not disclose the contents of this protocol to any 
other parties, unless such disclosure is required by government regulations or laws, without the 
prior written permission of Sunovion Pharmaceuticals Inc. 
Any data gathered during the conduct of this protocol and supplemental information (eg, a 
 
protocol amendment) that may be added to this document is also proprietary to Sunovion 
Pharmaceuticals Inc., and should be handled consistently with that stated above. 

Protocol SEP380-201, Version 2.00 
SEP-4199 
Confidential and Proprietary 
3 
04 June 2018 
EMERGENCY CONTACTS 
Table 1: Emergency Contact Information 
Role in Study 
Name 
Contact Information 
Responsible Physician 
Head of Global Clinical 
Research Psychiatry 
Sunovion Pharmaceuticals 
Inc. 
Telephone:  
Email:  
Medical Advisor 
 Associate Medical Director 
Medical Strategy & 
Science, Therapeutic 
Science and Strategy Unit 
IQVIA 
Telephone: US toll-free
 Intl: 
Email:  
24-Hour Serious Adverse 
Event/Pregnancy Reporting in 
the United States 
PPD Pharmacovigilance 
(PVG) 
Hotline Number:  Email:  United 
States 
Fax: 
 Outside United States 
Fax:  

Protocol SEP380-201, Version 2.00 
SEP-4199 
Confidential and Proprietary 
4 
04 June 2018 
1.
SYNOPSIS
Name of Sponsor: Sunovion Pharmaceuticals Inc. 
Name of Investigational Product: SEP-4199 
Name of Active Ingredient: Non-racemic amisulpride 
Proposed Indication: Major Depressive Episode Associated with Bipolar I Disorder (Bipolar I 
Depression) 
Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of SEP-4199 
for the Treatment of Major Depressive Episode Associated with Bipolar I Disorder (Bipolar I 
Depression) 
Study Centers: Approximately 85 sites in the United States (US), Europe, and Japan 
Study Objectives 
Primary Objective: 
•
To evaluate the efficacy of SEP-4199 200 mg/day and 400 mg/day compared with placebo
for major depressive episode associated with bipolar I depression (diagnosed by DSM-5
criteria) as measured by Montgomery-Asberg Depression Rating Scale (MADRS) total
score.
Secondary Efficacy Objective: 
•
To evaluate the effect of SEP-4199 200 mg/day and 400 mg/day compared with placebo on
severity of illness as measured by the Clinical Global Impression Bipolar Version, Severity
of Illness (CGI-BP-S) score (depression).
Pharmacokinetic Objectives: 
•
To evaluate the therapeutic plasma concentration range of SEP-4199 200 mg/day and
400 mg/day for major depressive episode associated with bipolar I disorder.
•
To determine the population pharmacokinetics (PK) of SEP-4199 200 mg/day and
400 mg/day.
Other Objectives: 
•
To determine the relationship between SEP-4199 PK and plasma prolactin for SEP-4199
200 mg/day and 400 mg/day.
•
To characterize the exposure-response relationship of SEP-4199 200 mg/day and
400 mg/day and symptoms as measured by MADRS using population pharmacokinetic
(PK)/ pharmacodynamics (PD).
•
To evaluate the effect of SEP-4199 200 mg/day and 400 mg/day compared with placebo on
anxiety symptoms, as measured by the Hamilton Rating Scale for Anxiety (HAM-A).
•
To evaluate treatment response, defined as ≥ 50% reduction from baseline on the MADRS
total score.
•
To evaluate the effect of SEP-4199 200 mg/day and 400 mg/day on symptom remission,
defined as a MADRS total score of ≤ 12 after 6 weeks of treatment.
•
To evaluate the effect of SEP-4199 200 mg/day and 400 mg/day on functional impairment
associated with bipolar depressive symptoms, as measured by the Sheehan Disability Scale
(SDS) total score.

Protocol SEP380-201, Version 2.00 
SEP-4199 
Confidential and Proprietary 
5 
04 June 2018 
Name of Sponsor: Sunovion Pharmaceuticals Inc. 
Name of Investigational Product: SEP-4199 
Name of Active Ingredient: Non-racemic amisulpride 
•
To evaluate the effect of SEP-4199 200 mg/day and 400 mg/day on symptom severity as
measured by the Quick Inventory of Depressive Symptomatology – Self Report
(QIDS-SR16) total score.
Safety Objectives: 
•
To evaluate the effect of SEP-4199 200 mg/day and 400 mg/day on treatment-emergent
mania, as assessed by the YMRS or an AE of mania or hypomania.
•
To evaluate safety and tolerability of SEP-4199 200 mg/day and 400 mg/day as measured
by physical examinations, 12-lead electrocardiograms (ECG) parameters, vital signs,
adverse event (AE) reports, clinical laboratory results, Columbia-Suicide Severity Rating
Scale (C-SSRS), Abnormal Involuntary Movement Scale (AIMS), Barnes Akathisia Rating
Scale (BARS), and the Modified Simpson-Angus Scale (SAS).
Study Design 
This is a randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study designed to 
evaluate the efficacy, safety, and tolerability of treatment with SEP-4199 monotherapy given as 
200 mg/day or 400 mg/day compared with placebo for the treatment of major depressive episode 
associated with bipolar I disorder (bipolar I depression). The study is projected to randomize 
approximately 294 subjects (98 subjects per treatment group) in the US and Europe to one of 
3 treatment groups in a 1:1:1 ratio (SEP-4199 200 mg/day or 400 mg/day, or placebo). 
In addition, a Japanese cohort will be included in the study to summarize efficacy and safety data for 
Japanese subjects with bipolar I depression. Approximately 45 subjects (15 subjects per treatment 
group) will be randomized in the Japanese cohort in a 1:1:1 ratio (SEP-4199 200 mg/day or 
400 mg/day, or placebo). 
The study will consist of Screening (up to 21 days), 6 weeks of treatment (42 days), and follow-up 
(7 [± 2] days after the last study drug dose) as shown in the following figure. If necessary, subjects may 
return to the clinic at any time for an unscheduled visit. 
Study Schematic – All Subjects 

Protocol SEP380-201, Version 2.00 
SEP-4199 
Confidential and Proprietary 
6 
04 June 2018 
Name of Sponsor: Sunovion Pharmaceuticals Inc. 
Name of Investigational Product: SEP-4199 
Name of Active Ingredient: Non-racemic amisulpride 
Screening Period (Day -22 to -2) 
Informed consent will be obtained from each subject before any study procedures are performed for this 
study. Study eligibility criteria will be assessed during this period, and subjects will be washed out from 
prior or concomitant medications, where applicable, prior to randomization. Psychotropic medications 
(eg, antipsychotic agents, antidepressants, and mood stabilizers) are to be discontinued as tolerated and 
clinically appropriate at least 3 days prior to randomization. 
Per local clinical practice, subjects may be hospitalized for up to 7 days during the Screening period. 
Further need for hospitalization during the Screening period will require consultation with the Medical 
Monitor. 
Baseline (Day -1) and Treatment Period (Day 1 through Day 42) 
Subjects who meet eligibility criteria at Screening will return to the study site on Day -1 for 
confirmation of screening evaluations as well as completion of predose assessments. Eligible subjects 
(based on confirmation of study entry criteria) will be randomized and dispensed study drug at Day -1. 
Per local clinical practice, subjects may be hospitalized for up to 7 days during the first week of 
treatment with double-blind study drug. Further need for hospitalization will require consultation with 
the Medical Monitor. 
Subjects will self-administer the study drug on an outpatient basis once daily with or without food 
beginning on Day 1 (the day after the Baseline visit) and continue for 6 weeks (the last dose of study 
drug will be self-administered by the subject at home on the morning of Visit 6). Subjects will be 
instructed to administer study drug as a single oral dose in the morning at approximately the same time 
each day. Clinic visits are to begin no later than 6 hours postdose, if possible. 
During the baseline (Day -1) and treatment period (Days 1 to 42), subjects will have clinic visits at 
Days -1, 7, 14, and 28. In order to facilitate scheduling of clinic visits, a window of ± 2 days will be 
allowed for each clinic visit. Subjects will have a telephone contact at Day 35 (± 2). 
End of Treatment (EOT)/Early Termination (ET) (Day 42 [± 2]) 
Subjects will have a clinic visit at Day 42 for assessments of efficacy and safety. Subjects who 
discontinue the study prior to this visit will undergo the procedures and assessments for this visit at the 
time of discontinuation. 
Follow-up Period (Day 49 [± 2]) 
All subjects who received at least one dose of study drug will have a follow-up visit for safety and 
tolerability assessments 7 (± 2) days after their last study drug dose. Assessment of potential withdrawal 
effects will also be made during the follow-up period. 
Efficacy, Safety, and PK/PD Assessments 
Efficacy will be evaluated using the MADRS, CGI-BP-S, and HAM-A. Treatment response and 
symptom remission will be assessed using the MADRS. Additional assessments will include evaluation 
of functional impairment associated with bipolar depressive symptoms using the SDS total score and 
symptom severity using the QIDS-SR16 total score. 
Safety and tolerability will be monitored throughout the study by physical examinations, ECGs, vital 
signs, adverse event monitoring, clinical laboratory tests, YMRS, and C-SSRS. Subjects who have 
significant findings for suicidal ideation upon completion of the C-SSRS at any time during the study 
must be referred to the investigator for follow-up evaluation. Assessment of potential withdrawal 
effects will be conducted via administration of the Physician’s Withdrawal Checklist. Movement 
disorders will be assessed by AIMS, BARS, and Modified SAS. A Data and Safety Monitoring Board 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
7 
 
04 June 2018 
Name of Sponsor: Sunovion Pharmaceuticals Inc. 
Name of Investigational Product: SEP-4199 
Name of Active Ingredient: Non-racemic amisulpride 
(DSMB) will review safety data at regular intervals during the study. 
Blood samples will be collected for population pharmacokinetics. Blood samples will be analyzed for 
plasma concentrations of R- and S-amisulpride and plasma prolactin. Prior to PK blood sample 
collection, subjects will record the date and time of their 3 most-recent study drug doses; the clinical 
site staff will record the dates and times of the 3 doses in the CRF (Visits 4 and 6 only). Plasma samples 
collected for PK concentration analysis may also be used for the additional characterization and/or 
bioanalytical method development of putative metabolites of amisulpride and for other exploratory 
measurements, if needed. 
Number of Subjects (planned) US and Europe 
Approximately 294 subjects (N = 98 per treatment group) will be randomized in the US and Europe. 
Number of Subjects (planned) Japanese Cohort 
Approximately 45 subjects (N = 15 per treatment group) will be randomized in Japan. 
Main Diagnosis and Criteria for Enrollment 
Primary Inclusion Criteria (not all inclusive): 
• 
Subject provides written informed consent to participate in the study. 
• 
Subject is 18 to 65 years of age, inclusive, at the time of informed consent with bipolar I 
disorder, current episode depressed with or without rapid cycling disease course (≥ 4 episodes 
of mood disturbance but < 8 episodes in the previous 12 months) with or without psychotic 
features (diagnosed by DSM-5 criteria, and confirmed by the Structured Clinical Interview for 
DSM-5-Clinical Trial Version [SCID-5-CT]). The current episode of major depression 
associated with bipolar I disorder must be confirmed by the investigator and noted in the source 
records. 
• 
Subject must have a lifetime history of at least one bipolar manic or mixed manic episode. 
It is strongly recommended that a reliable informant (eg, family member or caregiver) be 
available to confirm this history. 
• 
Subject’s current major depressive episode is ≥ 4 weeks and less than 12 months in 
duration. 
• 
Subject has a MADRS total score ≥ 22 at both Screening and Baseline. 
• 
Subject has a YMRS total score ≤ 12 at Screening. 
Primary Exclusion Criteria (not all inclusive): 
• 
Subject has a lifelong history or presence of symptoms consistent with a major psychiatric 
disorder other than bipolar I disorder as defined by DSM-5. Exclusionary disorders include 
but are not limited to moderate to severe alcohol use disorder (within past 12 months), 
substance use disorder (other than nicotine or caffeine) within past 12 months, bipolar II 
disorder, schizoaffective disorder, obsessive compulsive disorder, posttraumatic stress 
disorder. 
• 
Subject demonstrates a decrease (improvement) of ≥ 25% in MADRS total score from 
Screening to Baseline, or subject’s MADRS total score is < 22 at Baseline. 
• 
Subject has a history of non-response to an adequate (6-week) trial of three or more 
antidepressants (with or without mood stabilizers) during the current episode. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
8 
 
04 June 2018 
Name of Sponsor: Sunovion Pharmaceuticals Inc. 
Name of Investigational Product: SEP-4199 
Name of Active Ingredient: Non-racemic amisulpride 
• 
Subject is considered by the Investigator to be at imminent risk of suicide or injury to self, 
others, or answers “yes” to “Suicidal Ideation” item 4 (active suicidal ideation with some 
intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and 
intent) on the C-SSRS assessment at the Screening visit (in the past 90 days]) or Baseline. 
The complete listing of study entry criteria is provided in Section 8. 
Investigational Product, Dosage and Mode of Administration 
SEP-4199 will be supplied as 100 mg tablets and 200 mg tablets each containing a fixed ratio of 85:15 
(R-amisulpride:S-amisulpride). 
Two 100 mg tablets will be given for the 200 mg dose and two 200 mg tablets will be given for the 
400 mg dose. 
Study drug tablets will be self-administered by the subject orally once daily in the morning at 
approximately the same time each day beginning on Day 1. 
Duration of Treatment 
Double-blind treatment will be self-administered by the subject once daily for 6 weeks. 
Reference Therapy, Dosage and Mode of Administration 
Placebo will be supplied as tablets matching the active treatment. 
Placebo tablets will be self-administered by the subject orally once daily in the morning at 
approximately the same time each day beginning on Day 1. 
Prior and Concomitant Medications 
Treatment with all prior psychotropic medications (eg, antipsychotic agents, antidepressants, and mood 
stabilizers) must be discontinued as tolerated and clinically appropriate at least 3 days or 5 half-lives 
(whichever is longer) prior to randomization. Subjects treated with fluoxetine or olanzapine plus 
fluoxetine combination must discontinue these medications at least 28 days prior to randomization. 
Depot neuroleptics must have been discontinued at least one treatment cycle prior to randomization. 
Subjects treated with MAO inhibitors must discontinue these medications at least 21 days prior to 
randomization. 
Treatment with sedative hypnotics (for insomnia) is permitted during the screening period, but should 
be tapered as clinically appropriate to conform with and adequately prepare the subject for the protocol-
specified dosing limitations applicable to these agents following randomization. 
The use of herbal supplements or other complementary or alternative medications during the trial is not 
permitted. 
Further details are provided in Section 10.3. 
Criteria for Evaluation 
Primary Efficacy Endpoint: 
• 
Change from baseline in MADRS total score at Week 6. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
9 
 
04 June 2018 
Name of Sponsor: Sunovion Pharmaceuticals Inc. 
Name of Investigational Product: SEP-4199 
Name of Active Ingredient: Non-racemic amisulpride 
Secondary Efficacy Endpoint: 
• 
Change from baseline in global severity assessed by the CGI-BP-S score (depression) at 
Week 6. 
Pharmacokinetic Endpoints: 
• 
Plasma concentrations of R- and S-amisulpride. 
• 
Plasma concentrations of prolactin. 
Other Endpoints: 
• 
Number and percentage of treatment responders, defined as ≥ 50% reduction from baseline 
in MADRS total score at Week 6. 
• 
Time to treatment response, defined as ≥ 50% reduction from baseline MADRS total score. 
• 
Change from baseline in anxiety symptoms based on the HAM-A total score at Week 6. 
• 
Incidence of symptom remission, defined as a MADRS total score of ≤ 12 at Week 6. 
• 
Time to remission, defined as MADRS total score of ≤ 12. 
• 
Functional impairment assessed by change from baseline in the SDS total score at Week 6. 
• 
Subject self-report of overall depressive symptom severity, assessed by change from 
baseline in the QIDS-SR16 total score at Week 6. 
Safety Endpoints: 
• 
Incidence of treatment-emergent mania, defined as a YMRS score of ≥ 16 on any 
2 consecutive visits or at the final assessment, or an AE of mania or hypomania. 
• 
Incidence of adverse events (AEs), discontinuation due to AEs, and serious AEs (SAEs). 
• 
Changes in weight, clinical laboratory tests, vital signs, and ECG measurements. 
• 
Change from baseline in AIMS, BARS, and Modified SAS. 
• 
Frequency and severity of suicidal ideation and suicidal behavior using the 
Columbia-Suicide Severity Rating Scale (C-SSRS). 
Japanese Cohort Endpoints: 
• 
All efficacy, pharmacokinetic, pharmacodynamic, and safety endpoints will be evaluated 
and summarized for the Japanese cohort. 
Statistical Methods 
General Methodology 
The primary efficacy analysis will be based on the intention-to-treat (ITT) population, which includes 
all subjects who are randomized. The safety population includes all subjects who are randomized and 
receive at least 1 dose of study medication. In general, all analyses of the Japanese cohort are 
descriptive in nature and will be reported separately unless otherwise specified. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
10 
 
04 June 2018 
Name of Sponsor: Sunovion Pharmaceuticals Inc. 
Name of Investigational Product: SEP-4199 
Name of Active Ingredient: Non-racemic amisulpride 
Primary Efficacy Analysis: 
The primary efficacy estimand is defined as the efficacy of each SEP-4199 dose over placebo for 
6 weeks calculated as the difference in the primary efficacy endpoint (change from baseline in the 
MADRS total score at Week 6) between each SEP-4199 treatment group and the placebo treatment 
group in the ITT population. This estimand, which will only include those subjects who participated in 
sites located in the US and Europe provides an estimate of the efficacy of each SEP-4199 dose over 
placebo, should a subject be able to tolerate and adhere to treatment for 6 weeks. The analysis method 
makes a missing at random (MAR) assumption to the missing primary efficacy endpoints. 
A mixed model for repeated measures (MMRM) that includes terms for treatment, visit, region, 
baseline MADRS total score, and the treatment-by-visit interaction will be used for the primary efficacy 
analysis. An unstructured covariance matrix will be used for the within-subject correlation. 
The comparisons of SEP-4199 200 mg/day and SEP-4199 400 mg/day versus placebo at Week 6 will be 
adjusted for multiplicity using the truncated Hochberg (γ) procedure with truncation parameter, γ = 0.9 
(Dmitrenko 2017). 
To evaluate the robustness of the MMRM results for the primary efficacy endpoint with respect to the 
MAR assumption, sensitivity analyses based on a Missing Not At Random (MNAR) assumption will be 
performed. 
A supplementary analysis of the primary efficacy of SEP-4199 will be conducted to explore the dose 
response relationship using the Multiple Comparison Procedure – Modelling (MCP-Mod) methodology. 
Possible dose response shapes to assess include linear, quadratic, Emax, and sigmoidal Emax. The best 
model fit will be selected using the minimum Akaike information criterion out of the statistically 
significant multiple contrast tests based on optimal contrast coefficients. Once the best model is selected, 
target dose(s) of interest including the minimum effective dose (MED) will be explored. 
Secondary Efficacy Analyses: 
The CGI-BP-S score (depression) will be analyzed by the MMRM method described for the primary 
efficacy endpoint using the ITT population with the appropriate baseline used as the covariate. 
The CGI-BP-S secondary endpoint at Week 6 along with the primary endpoint at Week 6 will be tested 
using a mixture-based gatekeeping procedure to control the global familywise error rate (FWER). This 
gatekeeping procedure is constructed using two component procedures. Once the primary objective of 
at least one primary endpoint is met using a truncated Hochberg (γ = 0.9), the second component, the 
CGI-BP-S hypotheses, will be tested using a regular Hochberg procedure. A hypothesis is testable in a 
latter family only if the hypothesis in the former family associated with the same dose level is rejected. 
Other Efficacy Analyses: 
The HAM-A and the QIDS-SR16 total score will be analyzed by the MMRM method described for the 
primary efficacy endpoint using the ITT population with the appropriate baseline used as the covariate. 
The SDS and EuroQoL 5 dimensional questionnaire (EQ-5D-5L) total scores will be analyzed using an 
ANCOVA model with treatment, region as fixed effects, and appropriate baseline as a covariate. 
The MADRS total score responder proportions at Week 6 will be compared among the 3 treatment arms 
using logistic regression. This model will include treatment and region as fixed effects and baseline 
MADRS score as a covariate. 
The log rank testing method will be used to test for differences among the treatments for time to 
MADRS responder response. The analysis will be supplemented with Kaplan-Meier curves to illustrate 
the differences among the three treatments. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
11 
 
04 June 2018 
Name of Sponsor: Sunovion Pharmaceuticals Inc. 
Name of Investigational Product: SEP-4199 
Name of Active Ingredient: Non-racemic amisulpride 
A cumulative distribution curve of treatment response for each treatment group will be presented. 
Remission incidence rates will be analyzed similarly to the MADRS responder analysis. 
The R- and S-amisulpride and plasma prolactin concentrations will be listed and summarized 
descriptively by dose level. 
The complete methodology and results of the population pharmacokinetic and pharmacodynamic 
analyses will be reported separately. 
Safety Analyses: 
AEs (or SAEs) and AEs leading to discontinuation will be summarized by number and percentage of 
subjects for each treatment group by system organ class and preferred term. AEs will also be reported 
by maximum severity and by relationship to study drug. 
Mania incidence rates (YMRS) will be analyzed similarly to the MADRS responder analysis (as 
described above). 
Descriptive statistics will be provided by treatment for observed values or changes from baseline for 
weight, laboratory parameters, vital signs, and ECG parameters. The incidence of subjects with elevated 
QTcF intervals: (> 450 for males and > 470 for females) and (> 500 msec for males or females) and 
changes in QTc intervals ≥ 30 msec, but < 60 msec and ≥ 60 msec will be summarized by treatment 
group. 
Rank ANCOVA with adjustments for baseline value will be applied to change from baseline in serum 
prolactin, lipids, glucose, weight, and body mass index (BMI) for comparison between each SEP-4199 
group and placebo. 
Movement disorder measures (AIMS, BARS, and Modified SAS) will be analyzed using MMRM based 
on the change from baseline to Week 6. 
The frequency and severity of suicidal ideation or suicidal behavior in the C-SSRS will be provided for 
each time point as appropriate. 
Japanese Cohort Analyses: 
In general, descriptive statistics will be used to summarize the efficacy and safety of the Japanese 
cohort. An additional exploratory analysis with the Japanese cohort primary efficacy data will be 
performed by replacing region (US, EU) with region (US, EU, Japan) in the MMRM primary model. 
The Japanese cohort alone will also be analyzed using an MMRM method. 
In general, safety analyses will be repeated for the Japanese Cohort using descriptive statistics. 
Sample Size: 
A total sample size of 279 evaluable subjects in US and Europe (93 per treatment group: SEP-4199 
200 mg/day, SEP-4199 400 mg/day, and placebo) with a 2-sided global alpha of 0.05 will provide about 
90% power to reject at least 1 truly significant comparison and about 75% power to reject both truly 
significant comparisons using the truncated Hochberg (γ = 0.9) procedure, assuming treatment effect 
sizes of 0.44 for both doses of SEP-4199. The effect sizes were selected considering the data from the 
completed lurasidone bipolar depression study (Loebel 2014). This effect size corresponds to a 
treatment difference of -3.85 for a SEP-4199 dose with a common standard deviation of 8.745 on the 
MADRS scale change from baseline at Week 6. An upward adjustment of approximately 5% is used to 
compensate for information lost due to subjects who are randomized and do not provide any 
postbaseline primary efficacy data. The total sample size will be approximately 294 randomized 
subjects (or N = 98 subjects per treatment group). 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
12 
 
04 June 2018 
Name of Sponsor: Sunovion Pharmaceuticals Inc. 
Name of Investigational Product: SEP-4199 
Name of Active Ingredient: Non-racemic amisulpride 
The sample size was calculated using the Mediana package version 1.05 within R version 3.4.2 (R Core 
Team 2017). 
The sample size for the Japanese Cohort (45 total [N = 15 subjects per group], including 9 dropouts) 
provides more than 80% probability to have a treatment difference point estimate greater than zero for 
the MADRS. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
13 
04 June 2018 
Table 2: Schedule of Assessments 
 
Screen 
Baseline and Treatment 
EOT/ET 
Follow-up 
Study Visit Number 
Visit 1a 
Visit 2a,b 
Visit 3 
Visit 4 
Visit 5 
TC 
Visit 6c 
Visit 7 
Study Visit Day 
-22 to -2 
-1 
7±2 
14±2 
28±2 
35±2 
42±2 
49±2 
Study Procedures 
 
 
 
 
 
 
 
 
   Informed consent 
X 
 
 
 
 
 
 
 
   Inclusion/Exclusion Criteria Review 
X 
X 
 
 
 
 
 
 
   Randomization 
 
X 
 
 
 
 
 
 
   Dispense Study Drug 
 
X 
X 
X 
X 
 
 
 
   Study Drug Accountabilityd 
 
 
X 
X 
X 
 
X 
 
   Prior/Concomitant Medications 
X 
X 
X 
X 
X 
X 
X 
X 
   Pretreatment Event Monitoring 
X 
X 
 
 
 
 
 
 
   Adverse Event Monitoring 
 
 
X 
X 
X 
X 
X 
X 
   Schedule Next Visite 
X 
X 
X 
X 
X 
X 
X 
 
   Demographics 
X 
 
 
 
 
 
 
 
   Medical History 
X 
 
 
 
 
 
 
 
   Psychiatric History/Mental Statusf 
X 
 
 
 
 
 
 
 
   Structured Clinical Interview for DSM-Clinical Trial 
   Version (SCID-5-CT)g 
X 
 
 
 
 
 
 
 
   Physical Examination 
X 
X 
 
 
 
 
X 
X 
   Neurological Examination 
X 
X 
 
 
 
 
X 
 
   Height 
X 
 
 
 
 
 
 
 
   Weight (Including Body Mass Index)h 
X 
X 
 
 
 
 
X 
X 
   Waist Circumference 
 
X 
 
 
 
 
X 
X 
   Vital Signsi 
X 
X 
X 
X 
X 
 
X 
X 
   12-Lead Electrocardiogram (ECG) 
X 
X 
X 
X 
X 
 
X 
X 
   Montgomery-Asberg Depression Rating Scale (MADRS)j 
X 
X 
X 
X 
X 
 
X 
 
   Hamilton Rating Scale for Anxiety (HAM-A) 
 
X 
X 
X 
X 
 
X 
 
   Young Mania Rating Scale (YMRS)k 
X 
X 
X 
X 
X 
 
X 
X 
   Sheehan Disability Scale (SDS) 
 
X 
 
 
 
 
X 
 
   Quick Inventory of Depressive Symptomatology –  
   Self-Report (QIDS-SR16) 
 
X 
X 
X 
X 
 
X 
 
   Abnormal Involuntary Movement Scale (AIMS) 
 
X 
X 
X 
X 
 
X 
 
   Barnes Akathisia Rating Scale (BARS) 
 
X 
X 
X 
X 
 
X 
 
   Modified Simpson-Angus Scale (SAS) 
 
X 
X 
X 
X 
 
X 
 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
14 
 
04 June 2018 
Table 2: 
Schedule of Assessments (Continued) 
 
Screen 
Baseline and Treatment 
EOT/ET 
Follow-up 
Study Visit Number 
Visit 1a 
Visit 2a,b 
Visit 3 
Visit 4 
Visit 5 
TC 
Visit 6c 
Visit 7 
Study Visit Day 
-22 to -2 
-1 
7±2 
14±2 
28±2 
35±2 
42±2 
49±2 
   Columbia-Suicide Severity Rating Scale (C-SSRS)l 
X 
X 
X 
X 
X 
 
X 
X 
   Physician Withdrawal Checklist 
 
 
 
 
 
 
X 
X 
   Clinical Global Impression – Bipolar Version-Severity of 
   Illness (CGI-BP-S) 
 
X 
X 
X 
X 
 
X 
 
   EuroQoL-5D (EQ-5D-5L) 
 
X 
 
 
 
 
X 
 
   Hepatitis B/C 
X 
 
 
 
 
 
 
 
   Urine Drug Screen 
X 
X 
 
X 
 
 
X 
X 
   Serum Thyroid Stimulating Hormone 
X 
 
 
 
 
 
 
 
   Serum Follicle Stimulating Hormone (Female Subjects) 
X 
 
 
 
 
 
 
 
   Serum β-hCG (Female Subjects of childbearing potential)m 
X 
 
 
 
 
 
 
 
   Urine β-hCG (Female Subjects of childbearing potential)m 
 
X 
 
X 
 
 
X 
X 
   Hematology, Serum Chemistry, and Urinalysisn 
X 
X 
 
X 
 
 
X 
X 
   Serum Prolactino,p 
X 
X 
 
X 
 
 
X 
X 
   Hemoglobin A1c (HbA1c) 
X 
X 
 
 
 
 
X 
 
   Lipid Paneln 
X 
X 
 
 
 
 
X 
 
   Serum Insulin 
X 
X 
 
 
 
 
X 
 
   High-sensitivity (hs) CRP 
X 
X 
 
 
 
 
X 
 
   Blood Sample for R- and S-Amisulpride PK and Plasma 
   prolactinp 
X 
X 
 
X 
 
 
X 
X 
Abbreviations: BMI = body mass index; CRF = case report form; CRP = C-reactive protein; DSM-5 = The Diagnostic and Statistical Manual of Mental 
Disorders, Fifth Edition; EOT = End of Treatment; ET = Early Termination; hCG = human chorionic gonadotropin; PK = pharmacokinetics; TC = Telephone 
Contact. 
a Per local clinical practice, subjects may be hospitalized for up to 7 days during the Screening period and/or during the first week of treatment with double-blind 
investigational product. Further need for hospitalization will require consultation with the Medical Monitor. 
b Visit 2 is defined as the baseline visit. Study drug will be dispensed at Visit 2/Day -1, and subjects will be instructed to take their first dose of study drug the 
following morning (Day 1). 
c Visit 6 is the End of Treatment/Early Termination visit. Subjects who discontinue the study prior to Visit 6 will have all Visit 6 procedures performed at the 
time of discontinuation. All subjects who complete the treatment period and those who discontinue early will complete a follow-up visit 7 (±2) days after the 
last dose of study drug. 
d Clinical site staff will record the date and time of the 3 doses prior to the study visit in the source (all visits) and CRF (Visits 4 and 6 only), based on subject 
self-report. 
Footnotes continue on next page. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
15 
 
04 June 2018 
e Instruct subject to record dosing date and time of the last 3 doses prior to the study visit on the blisterpack wallet and bring back all used/unused study drug and 
packaging to next visit. 
f Includes a psychiatric history form that will include variables related to duration of illness, treatment response (eg, prior medications used to treat bipolar 
disorder) and other similar variables. 
g The SCID-5-CT will be used to support the DSM-5 diagnosis and must be administered by a qualified rater at the site. 
h BMI will be calculated by clinical site staff at Screening and recorded in the CRF. At visits 2, 6, and 7, BMI does not need to be calculated by the clinical site 
staff as it will be calculated in the analysis. 
i Vital signs measurements will include orthostatic changes in blood pressure and heart rate. After being in a supine position for ≥ 5 minutes, systolic and 
diastolic blood pressures, respiratory rate, pulse rate, and temperature will be collected. Blood pressure and pulse rate will be taken again after standing for 2 to 
4 minutes. The same arm should be used during each assessment of blood pressure and pulse rate throughout the study. 
j To be eligible for enrollment, subjects must have a MADRS total score ≥ 22 at Screening. Subjects who demonstrate a decrease (improvement) of ≥ 25% in 
MADRS total score from Screening to Baseline, or who have a MADRS total score < 22 at Baseline will not be eligible for enrollment (see Section 24, 
Appendix V). 
k To be eligible for enrollment, subjects must have a YMRS total score ≤ 12 at Screening. 
l At the Screening visit, the baseline/screening version will be completed; for all subsequent visits, the “Since Last Visit” version of the C-SSRS will be 
administered. 
m Any positive urine β-human chorionic gonadotropin (hCG) test should be confirmed by serum β-hCG. 
n Subjects are to fast overnight for at least 8 hours (no food after midnight) prior to blood sample collection for laboratory testing at Visits 2 and 6; it is also 
recommended for Visit 1 so as to avoid potential retests. 
o Prolactin levels (serum and plasma) will be blinded except for results from Visit 1 (Screening). 
p Blood sample for SEP-4199 population pharmacokinetic analysis for R- and S-enantiomers and/or plasma prolactin measurement will be collected at Visits 1, 
2, 4, 6 and 7, with a record of the time of last 3 doses on the CRF at Visits 4 and 6. The blood sample will be collected at time of clinical safety laboratory test 
sample collection. Plasma concentrations of R- and S-amisulpride and plasma prolactin levels will be measured. Remaining plasma from samples may also be 
used for the additional characterization and/or bioanalytical method development of putative metabolites of amisulpride and for other exploratory 
measurements, if needed. 
 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
16 
04 June 2018 
2. 
TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF 
FIGURES 
TABLE OF CONTENTS 
RESTRICTED DISTRIBUTION OF PROTOCOLS ......................................................................2 
EMERGENCY CONTACTS...........................................................................................................3 
1. 
SYNOPSIS ...................................................................................................................4 
2. 
TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF FIGURES ...............16 
3. 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS.............................22 
4. 
INTRODUCTION ......................................................................................................25 
4.1. 
Background .................................................................................................................25 
4.2. 
Study Conduct Rationale ............................................................................................25 
4.3. 
Risk-Benefit Assessment ............................................................................................25 
5. 
STUDY OBJECTIVES ..............................................................................................26 
5.1. 
Primary Objective .......................................................................................................26 
5.2. 
Secondary Efficacy Objective ....................................................................................26 
5.3. 
Pharmacokinetic Objectives .......................................................................................26 
5.4. 
Other Objectives .........................................................................................................26 
5.5. 
Safety Objectives ........................................................................................................27 
6. 
STUDY ENDPOINTS ................................................................................................27 
6.1. 
Primary Efficacy Endpoint .........................................................................................27 
6.2. 
Secondary Efficacy Endpoint .....................................................................................27 
6.3. 
Pharmacokinetic Endpoints ........................................................................................27 
6.4. 
Other Endpoints ..........................................................................................................27 
6.5. 
Safety Endpoints .........................................................................................................28 
6.6. 
Japanese Cohort Endpoints .........................................................................................28 
7. 
INVESTIGATIONAL PLAN .....................................................................................29 
7.1. 
Overall Study Design ..................................................................................................29 
7.2. 
Treatment Assignment and Blinding ..........................................................................31 
7.2.1. 
Treatment Assignment ................................................................................................31 
7.2.2. 
Blinding ......................................................................................................................31 
7.2.3. 
Emergency Unblinding Procedures ............................................................................32 
7.3. 
Rationale .....................................................................................................................32 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
17 
04 June 2018 
7.3.1. 
Rationale for the Dosages ...........................................................................................32 
7.3.2. 
Rationale for the Study Population .............................................................................33 
7.3.3. 
Rationale for the Endpoints ........................................................................................33 
7.4. 
Prevention of Missing Data ........................................................................................33 
8. 
SELECTION OF SUBJECTS ....................................................................................34 
8.1. 
Subject Inclusion Criteria ...........................................................................................34 
8.2. 
Subject Exclusion Criteria ..........................................................................................35 
9. 
STUDY DRUG MATERIALS AND MANAGEMENT ...........................................38 
9.1. 
Description of Study Drug ..........................................................................................38 
9.2. 
Study Drug Packaging and Labeling ..........................................................................38 
9.2.1. 
Package Description ...................................................................................................38 
9.2.2. 
Labeling Description ..................................................................................................38 
9.3. 
Study Drug Storage .....................................................................................................39 
9.4. 
Dispensing of Study Drug ..........................................................................................39 
9.5. 
Study Drug Accountability .........................................................................................39 
9.6. 
Study Drug Handling and Disposal ............................................................................40 
10. 
TREATMENT OF SUBJECTS ..................................................................................41 
10.1. 
Study Drug ..................................................................................................................41 
10.2. 
Treatment Compliance ................................................................................................41 
10.3. 
Prior and Concomitant Medications and Therapies ....................................................41 
10.3.1. 
Prior Medications ........................................................................................................41 
10.3.2. 
Concomitant Nonpsychotropic Medications ..............................................................42 
10.3.3. 
Concomitant Psychotropic/Antipsychotic Medications .............................................42 
10.3.4. 
Prohibited Medications ...............................................................................................43 
10.4. 
Contraception Requirements ......................................................................................43 
10.5. 
Guidance for Overdose ...............................................................................................45 
11. 
STUDY ASSESSMENTS ..........................................................................................46 
11.1. 
Demographics and Baseline Characteristics ...............................................................46 
11.2. 
Diagnostic Scales to Determine Study Eligibility ......................................................46 
11.2.1. 
SCID-5-CT .................................................................................................................46 
11.2.2. 
Young Mania Rating Scale (YMRS) ..........................................................................46 
11.2.3. 
Montgomery-Asberg Depression Rating Scale (MADRS) ........................................47 
11.3. 
Efficacy Assessments .................................................................................................47 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
18 
04 June 2018 
11.3.1. 
Montgomery-Asberg Depression Rating Scale (MADRS) ........................................47 
11.3.2. 
Clinical Global Impressions – Severity: Bipolar Version (CGI-BP-S -
 Depression) ................................................................................................................48 
11.3.3. 
Hamilton Rating Scale for Anxiety (HAM-A) ...........................................................48 
11.3.4. 
Sheehan Disability Scale (SDS) .................................................................................48 
11.3.5. 
Quick Inventory of Depressive Symptomatology – Self-Report 16-Item 
(QIDS-SR16) ..............................................................................................................48 
11.3.6. 
EuroQoL 5-D (EQ-5D-5L) .........................................................................................49 
11.4. 
Safety Assessments .....................................................................................................49 
11.4.1. 
Pretreatment Events and Adverse Events ...................................................................49 
11.4.2. 
Clinical Laboratory Tests ...........................................................................................49 
11.4.3. 
Vital Signs ..................................................................................................................50 
11.4.4. 
Centrally-read ECG ....................................................................................................50 
11.4.5. 
Safety Scales ...............................................................................................................50 
11.4.5.1. 
Columbia-Suicide Severity Rating Scale (C-SSRS) ...................................................50 
11.4.5.2. 
Young Mania Rating Scale (YMRS) ..........................................................................51 
11.4.5.3. 
Abnormal Involuntary Movement Scale (AIMS) .......................................................51 
11.4.5.4. 
Barnes Akathisia Rating Scale (BARS) .....................................................................51 
11.4.5.5. 
Modified Simpson-Angus Scale (SAS) ......................................................................51 
11.4.5.6. 
Physician Withdrawal Checklist .................................................................................52 
11.5. 
Pharmacokinetic Assessments ....................................................................................52 
11.6. 
Study Visits and Assessments ....................................................................................52 
11.6.1. 
Screening: Visit 1 (Day -22 to -2) ..............................................................................52 
11.6.2. 
Baseline and Treatment Period: Day -1 to Day 42 .....................................................54 
11.6.2.1. 
Baseline: Visit 2 (Day -1) ...........................................................................................54 
11.6.2.2. 
Visit 3 (Day 7 ± 2) ......................................................................................................55 
11.6.2.3. 
Visit 4 (Day 14 ± 2) ....................................................................................................56 
11.6.2.4. 
Visit 5 (Day 28 ± 2) ....................................................................................................57 
11.6.2.5. 
Telephone Contact (Day 35 ± 2) ................................................................................58 
11.6.3. 
End of Treatment/Early Termination: Visit 6 (Day 42 ± 2) .......................................58 
11.6.4. 
Follow-up: Visit 7 (Day 49 ± 2) .................................................................................59 
12. 
SAFETY REPORTING ..............................................................................................61 
12.1. 
Definitions ..................................................................................................................61 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
19 
04 June 2018 
12.1.1. 
Adverse Events ...........................................................................................................61 
12.1.2. 
Serious Adverse Events ..............................................................................................61 
12.2. 
Objective Findings ......................................................................................................62 
12.3. 
Collection and Recording of Adverse Events .............................................................63 
12.4. 
Immediately Reportable Events ..................................................................................64 
12.4.1. 
Serious Adverse Event ................................................................................................65 
12.4.2. 
Pregnancy ...................................................................................................................65 
12.5. 
Data and Safety Monitoring Board .............................................................................66 
13. 
TERMINATION OF SUBJECT FROM STUDY/ DISCONTINUATION OF 
STUDY DRUG ...........................................................................................................67 
13.1. 
Criteria for Subject Termination .................................................................................67 
14. 
STUDY TERMINATION ..........................................................................................68 
15. 
STATISTICS ..............................................................................................................69 
15.1. 
Sample Size ................................................................................................................69 
15.2. 
Analysis Populations ..................................................................................................69 
15.3. 
Data Analysis ..............................................................................................................70 
15.3.1. 
Subject Disposition .....................................................................................................70 
15.3.2. 
Drug Exposure and Compliance .................................................................................70 
15.3.3. 
Important Protocol Deviations ....................................................................................71 
15.3.4. 
Demographic and Baseline Characteristics ................................................................71 
15.3.5. 
Efficacy Analyses .......................................................................................................72 
15.3.5.1. 
Primary Efficacy Endpoint Analysis ..........................................................................72 
15.3.5.2. 
Secondary Efficacy Endpoint Analyses ......................................................................73 
15.3.5.3. 
Other Efficacy Endpoint Analyses .............................................................................74 
15.3.5.4. 
Adjustment for Multiplicity ........................................................................................74 
15.3.5.5. 
Efficacy Subgroup Analyses .......................................................................................75 
15.3.6. 
Safety Analyses ..........................................................................................................75 
15.3.6.1. 
Adverse Events ...........................................................................................................76 
15.3.6.2. 
Treatment-Emergent Mania ........................................................................................76 
15.3.6.3. 
Clinical Laboratory Assessments ...............................................................................77 
15.3.6.4. 
ECGs ...........................................................................................................................77 
15.3.6.5. 
Vital Signs ..................................................................................................................78 
15.3.6.6. 
Movement Disorder Measures ....................................................................................78 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
20 
04 June 2018 
15.3.6.7. 
Columbia-Suicide Severity Rating Scale (C-SSRS) ...................................................78 
15.3.6.8. 
Neurological and Physical Examination .....................................................................78 
15.3.6.9. 
Concomitant Medications ...........................................................................................78 
15.3.6.10. Safety Subgroup Analyses ..........................................................................................79 
15.3.7. 
Pharmacokinetic Analysis ..........................................................................................79 
15.3.8. 
Interim Analysis ..........................................................................................................79 
15.3.9. 
Treatment of Missing Data .........................................................................................80 
16. 
PROCEDURE FOR CLINICAL STUDY QUALITY CONTROL/DATA 
COLLECTION, MANAGEMENT, AND QUALITY ASSURANCE ......................81 
16.1. 
Data Collection/Electronic Data Capture (EDC) ........................................................81 
16.2. 
Computerized Systems Used for Source Data ............................................................81 
16.3. 
Study Monitoring ........................................................................................................82 
16.4. 
Audits ..........................................................................................................................82 
16.5. 
Study Documentation .................................................................................................83 
16.6. 
Clinical Laboratory Certification and Normal Values ................................................83 
17. 
ETHICAL AND REGULATORY OBLIGATIONS..................................................84 
17.1. 
Study Conduct ............................................................................................................84 
17.2. 
Institutional Review Board/Independent Ethics Committee ......................................84 
17.3. 
Informed Consent .......................................................................................................85 
17.4. 
Subject Privacy ...........................................................................................................85 
17.5. 
Protocol Amendments and Emergency Deviations ....................................................86 
17.6. 
Records Retention .......................................................................................................86 
17.7. 
Inspection of Records .................................................................................................86 
17.8. 
Financial Disclosure ...................................................................................................86 
17.9. 
Publication Policy .......................................................................................................87 
17.10. 
Compensation .............................................................................................................87 
18. 
REFERENCES ...........................................................................................................88 
19. 
INVESTIGATOR APPROVAL .................................................................................90 
20. 
APPENDIX I. CARDIAC SAFETY MONITORING (ECG) ....................................91 
21. 
APPENDIX II. CLINICAL LABORATORY TESTS ...............................................92 
22. 
APPENDIX III. BLOOD SAMPLE COLLECTION AND HANDLING 
GUIDELINES FOR PHARMACOKINETIC AND PLASMA PROLACTIN 
ASSESSMENTS.........................................................................................................93 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
21 
04 June 2018 
23. 
APPENDIX IV. PROHIBITED DRUGS KNOWN TO CONSISTENTLY 
PROLONG THE QT INTERVAL .............................................................................94 
24. 
APPENDIX V. MINIMUM MADRS TOTAL SCORE CRITERIA AT 
BASELINE .................................................................................................................95 
 
LIST OF TABLES 
Table 1: 
Emergency Contact Information ...................................................................................3 
Table 2: 
Schedule of Assessments ............................................................................................13 
Table 3: 
List of Abbreviations ..................................................................................................22 
Table 4: 
Definition of Key Study Terms ..................................................................................24 
Table 5: 
Investigational Product ...............................................................................................38 
Table 6: 
Computerized Systems Used for Source Data ............................................................81 
 
LIST OF FIGURES 
Figure 1: 
Study Schematic – All Subjects ..................................................................................29 
Figure 2: 
Hierarchy of Testing for Primary and Secondary Endpoints......................................75 
 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
22 
04 June 2018 
3. 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
The abbreviations and the definition of key study terms used in the clinical study protocol are 
shown in Table 3 and Table 4. 
Table 3: List of Abbreviations 
Abbreviation 
Full Form 
AE 
Adverse event 
AIMS 
Abnormal Involuntary Movement Scale 
ALT 
Alanine aminotransferase 
AST 
Aspartate aminotransferase 
BARS 
Barnes Akathisia Rating Scale 
BMI 
Body mass index  
CFR 
Code of Federal Regulations 
CGI-BP-S 
Clinical Global Impression – Bipolar Version-Severity of Illness 
CRF 
Case report form (or electronic case report form) 
CRO 
Contract research organization 
C-SSRS 
Columbia-Suicide Severity Rating Scale 
CV 
Coefficient of variation 
DBL 
Database lock 
DMC 
Data Monitoring Committee 
DSMB 
Data and Safety Monitoring Board 
ECG 
Electrocardiogram 
EDC 
Electronic data capture 
EOS 
End of study 
EPS 
Extrapyramidal symptoms 
EQ-5D-5L 
EuroQoL 5 dimensional questionnaire 
ET 
Early termination 
EU 
European Union 
FDA 
US Food and Drug Administration 
GCP 
Good Clinical Practice 
GMP 
Good Manufacturing Practice 
HAM-A 
Hamilton Rating Scale for Anxiety 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
23 
04 June 2018 
Table 3: 
List of Abbreviations (Continued) 
Abbreviation 
Full Form 
HbA1c 
Hemoglobin A1c 
hCG 
Human chorionic gonadotropin 
hs 
High sensitivity 
ICF 
Informed consent form 
ICH 
International Council on Harmonisation 
IEC 
Independent Ethics Committee 
IPD 
Important protocol deviation 
IRB 
Institutional Review Board 
IUD 
Intrauterine device 
IXRS 
Interactive Voice/Web-based Response System 
MADRS 
Montgomery-Asberg Depression Rating Scale 
MedDRA 
Medical Dictionary for Regulatory Activities 
MAO 
Monoamine oxidase 
OTC 
Over-the-counter 
PCS 
Potentially clinically significant 
PK 
Pharmacokinetic(s) 
PR 
Time between P wave and QRS in electrocardiography 
PT 
Preferred term 
PVG 
Pharmacovigilance 
QIDS 
Quick Inventory of Depressive Symptomatology – Self-Report 
QRS 
Electrocardiographic wave (complex or interval) 
QT 
Electrocardiographic interval from the beginning of the QRS 
complex to the end of the T wave 
QTc 
QT interval corrected for heart rate 
RO50 
Dose (mg) for 50% occupancy 
RR 
RR interval 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SAS 
Simpson-Angus Scale 
SCID-CT 
Structured Clinical Interview for DSM-Clinical Trial Version 
SDS 
Sheehan Disability Scale 
SOC 
System organ class 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
24 
04 June 2018 
Table 3: 
List of Abbreviations (Continued) 
Abbreviation 
Full Form 
SOP 
Standard Operating Procedure 
TdP 
Torsades de pointes 
US 
United States 
WHO-DD 
World Health Organization drug dictionary 
YMRS 
Young Mania Rating Scale 
 
Table 4: Definition of Key Study Terms 
Terms 
Definition of terms 
CRF 
A printed, optical, or electronic document designed to record all 
of the protocol required information to report to the Sponsor for 
each study subject. 
Screened Subject 
Any subject who signed the study specific informed consent and 
completed at least one study related procedure. 
Screen Failures 
Any subject who signed the study specific informed consent but 
either failed to meet study requirements during screening or met 
study requirements at screening but was not enrolled/randomized. 
Study Drug (or 
Study medication) 
Term to cover investigational drug, placebo, and/or active 
control. 
Treatment Period 
The period of the study in which the study drug is administered. 
Randomized Subject 
Any subject who was randomized into the treatment period of the 
study and was assigned a randomization number. 
Enrolled Subject 
Any subject who was successfully screened and enrolled into the 
pre-randomization period of the study. 
Randomization 
Failures 
Any subject who was enrolled but not randomized. 
Completed Subject 
Any subject who participated throughout the duration of the 
treatment period, up to and including Visit 6. 
Early Termination 
Subject 
Any subject who was successfully screened and randomized into 
the treatment period of the study, but did not complete the 
treatment period of the study. 
End of Treatment 
The day that the subject receives the protocol-defined last dose of 
the study drug. 
End of Study 
The day of the last visit by the last subject in the study. 
 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
25 
04 June 2018 
4. 
INTRODUCTION 
4.1. 
Background 
Bipolar spectrum illness (BD I, BD II, BD NOS) is estimated to affect 4.4% of the US 
population (Merikangas 2007). Bipolar disorder causes more marked functional impairment 
(Shippee 2011) and has a greater impact on quality of life than unipolar depression 
(Gutierrez-Rojas 2008). Bipolar patients spend considerably more time in depressive than in 
manic states over the course of their illnesses (Judd 2002, Judd 2003), and depressive symptoms 
therefore contribute more to impaired functioning, caregiver/family burden and economic costs 
than do manic/mixed symptoms (Miller 2014). 
The treatment of bipolar depression is challenging, due to the complexity and heterogeneity of 
clinical presentations, which may involve mixed symptoms with depression predominating. 
Although the pharmacologic treatment of bipolar depression continues to be dominated by 
three major classes of drugs, the anticonvulsants, atypical antipsychotics, and serotonergic 
antidepressants, these treatments have significant limitations including tolerability and 
undesirable side effects such as metabolic derangement, weight gain, sedation/somnolence, 
sexual dysfunction, extrapyramidal symptoms and akathisia (Kemp 2014). In addition, treatment 
of bipolar depression with antidepressants remains controversial due to concerns about switching 
patients into hypomania, mania, or more rapid cycling (APA 2002). 
Amisulpride is approved in Italy, Czech Republic, and Portugal for the treatment of dysthymia at 
a low dose of 50 mg/d (Lecrubier 1997). In vitro radioligand binding studies show that racemic 
amisulpride has high affinity for serotonin 5-HT7 receptors in addition to dopamine D2 receptors 
(Abbas 2009). Preclinical pharmacology studies using 5-HT7 knockout mice suggest that the 
antidepressant-like effects of amisulpride are mediated via 5-HT7 receptor antagonism 
(Abbas 2009). 
Sunovion is developing SEP-4199 for the treatment of major depressive episode associated with 
bipolar I disorder. 
4.2. 
Study Conduct Rationale 
The current study is designed to evaluate SEP-4199 for the treatment of major depressive 
episode associated with bipolar I disorder. 
4.3. 
Risk-Benefit Assessment 
The clinical efficacy of amisulpride on depressive symptoms in mood disorders 
(Montgomery 2002) has been demonstrated at dose levels associated with relatively low 
D2 receptor occupancy. To improve the benefit/risk profile of amisulpride in mood disorders, 
SEP-4199 has been designed with a non-racemic ratio of enantiomers (85% R-amisulpride: 
15% S-amisulpride) designed to optimally target ≤ 50% D2 occupancy. In this way, SEP-4199 
maximizes the 5-HT7 antagonist activity of amisulpride while reducing the level of 
D2 antagonism to the minimum associated with antidepressant benefit, in order to limit 
D2-associated undesirable side effects. This pharmacologic profile is expected to confer 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
26 
04 June 2018 
significant antidepressant benefits in those patients with more severe forms of depression, such 
as depressive episodes associated with bipolar disorder, and in patients with disorders 
characterized by mixed mood/psychotic symptoms. 
5. 
STUDY OBJECTIVES 
5.1. 
Primary Objective 
• To evaluate the efficacy of SEP-4199 200 mg/day and 400 mg/day compared with 
placebo for major depressive episode associated with bipolar I disorder (diagnosed by 
DSM-5 criteria) as measured by Montgomery-Asberg Depression Rating Scale 
(MADRS) total score. 
5.2. 
Secondary Efficacy Objective 
• To evaluate the effect of SEP-4199 200 mg/day and 400 mg/day compared with 
placebo on severity of illness as measured by the Clinical Global Impression Bipolar 
Version, Severity of Illness (CGI-BP-S) score (depression). 
5.3. 
Pharmacokinetic Objectives 
• To evaluate the therapeutic plasma concentration range of SEP-4199 200 mg/day and 
400 mg/day for major depressive episode associated with bipolar I disorder. 
• To determine the population pharmacokinetics (PK) of SEP-4199 200 mg/day and 
400 mg/day. 
5.4. 
Other Objectives 
• To determine the relationship between SEP-4199 PK and plasma prolactin for 
SEP-4199 200 mg/day and 400 mg/day. 
• To characterize the exposure-response relationship of SEP-4199 200 mg/day and 
400 mg/day and symptoms as measured by MADRS using population 
pharmacokinetic (PK)/pharmacodynamics (PD). 
• To evaluate the effect of SEP-4199 200 mg/day and 400 mg/day compared with 
placebo on anxiety symptoms, as measured by the Hamilton Rating Scale for Anxiety 
(HAM-A). 
• To evaluate treatment response, defined as ≥ 50% reduction from baseline on the 
MADRS total score. 
• To evaluate the effect of SEP-4199 200 mg/day and 400 mg/day on symptom 
remission, defined as a MADRS total score of ≤ 12 after 6 weeks of treatment. 
• To evaluate the effect of SEP-4199 200 mg/day and 400 mg/day on functional 
impairment associated with bipolar depressive symptoms, as measured by the 
Sheehan Disability Scale (SDS) total score. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
27 
04 June 2018 
• To evaluate the effect of SEP-4199 200 mg/day and 400 mg/day on symptom severity 
as measured by the Quick Inventory of Depressive Symptomatology-Self Report 
(QIDS-SR16) total score. 
5.5. 
Safety Objectives 
• To evaluate the effect of SEP-4199 200 mg/day and 400 mg/day on 
treatment-emergent mania, as assessed by the YMRS or an AE of mania or 
hypomania. 
• To evaluate safety and tolerability of SEP-4199 200 mg/day and 400 mg/day as 
measured by physical examinations, 12-lead electrocardiograms (ECG) parameters, 
vital signs, adverse event (AE) reports, clinical laboratory results, Columbia-Suicide 
Severity Rating Scale (C-SSRS), Abnormal Involuntary Movement Scale (AIMS) 
Barnes Akathisia Rating Scale (BARS), and the Simpson-Angus Scale (SAS). 
6. 
STUDY ENDPOINTS 
6.1. 
Primary Efficacy Endpoint 
• Change from baseline in MADRS total score at Week 6. 
6.2. 
Secondary Efficacy Endpoint 
• Change from baseline in global severity assessed by the CGI-BP-S score (depression) 
at Week 6. 
6.3. 
Pharmacokinetic Endpoints 
• Plasma concentrations of R- and S-amisulpride. 
• Plasma concentrations of prolactin. 
6.4. 
Other Endpoints 
• Number and percentage of treatment responders, defined as ≥ 50% reduction from 
baseline in MADRS total score at Week 6. 
• Time to treatment response, defined as ≥ 50% reduction from baseline MADRS total 
score. 
• Change from baseline in anxiety symptoms based on the HAM-A total score at 
Week 6. 
• Incidence of symptom remission, defined as a MADRS total score of ≤ 12 at Week 6. 
• Time to remission, defined as MADRS total score of ≤ 12. 
• Functional impairment assessed by change from baseline in the SDS total score at 
Week 6. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
28 
04 June 2018 
• Subject self-report of overall depressive symptom severity, assessed by change from 
baseline in the QIDS-SR16 total score at Week 6. 
6.5. 
Safety Endpoints 
• Incidence of treatment-emergent mania, defined as a YMRS score of ≥ 16 on any 
2 consecutive visits or at the final assessment, or an AE of mania or hypomania. 
• Incidence of adverse events (AEs), discontinuation due to AEs, and serious AEs 
(SAEs). 
• Changes in weight, clinical laboratory tests, vital signs, and ECG parameters. 
• Change from baseline in AIMS, BARS, and SAS. 
• Frequency and severity of suicidal ideation and suicidal behavior using the 
Columbia-Suicide Severity Rating Scale (C-SSRS). 
6.6. 
Japanese Cohort Endpoints 
• All efficacy, pharmacokinetic, pharmacodynamic, and safety endpoints will be 
evaluated and summarized for the Japanese cohort. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
29 
04 June 2018 
7. 
INVESTIGATIONAL PLAN 
7.1. 
Overall Study Design 
This is a randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study 
designed to evaluate the efficacy, safety, and tolerability of treatment with SEP-4199 
monotherapy given as 200 mg/day or 400 mg/day compared with placebo for the treatment of 
major depressive episode associated with bipolar I disorder (bipolar I depression). The study is 
projected to randomize approximately 294 subjects (98 subjects per treatment group) in the US 
and Europe to one of 3 treatment groups in a 1:1:1 ratio (SEP-4199 200 mg/day or 400 mg/day, 
or placebo). 
In addition, a Japanese cohort will be included in the study to summarize efficacy and safety data 
for Japanese subjects with bipolar I depression. Approximately 45 subjects (15 subjects per 
treatment group) will be randomized in the Japanese cohort in a 1:1:1 ratio (SEP-4199 
200 mg/day or 400 mg/day, or placebo). 
The study will consist of Screening (up to 21 days), 6 weeks of treatment (42 days), and 
follow-up (7 [±2] days after the last study drug dose). A study schematic is presented in Figure 1. 
Details of the study assessments and other procedures to be performed at each visit are presented 
in Table 2, Schedule of Assessments, and Section 11, Study Assessments. If necessary, subjects 
may return to the clinic at any time for an unscheduled visit. 
Figure 1: 
Study Schematic – All Subjects 
 
Screening Period (Day -22 to -2) 
Informed consent will be obtained from each subject before any study procedures are performed 
for this study. Study eligibility criteria will be assessed during this period, and subjects will be 
washed out from prior or concomitant medications, where applicable, prior to randomization. 
Psychotropic medications (eg, antipsychotic agents, antidepressants, and mood stabilizers) are to 
be discontinued as tolerated and clinically appropriate at least 3 days prior to randomization. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
30 
04 June 2018 
Per local clinical practice, subjects may be hospitalized for up to 7 days during the Screening 
period. Further need for hospitalization during the Screening period will require consultation 
with the Medical Monitor. 
Baseline (Day -1) and Treatment Period (Day 1 through Day 42) 
Subjects who meet eligibility criteria at Screening will return to the study site on Day -1 for 
confirmation of screening evaluations as well as completion of predose assessments. Eligible 
subjects (based on confirmation of study entry criteria) will be randomized and dispensed study 
drug at Day -1. 
Per local clinical practice, subjects may be hospitalized for up to 7 days during the first week of 
treatment with double-blind study drug. Further need for hospitalization will require consultation 
with the Medical Monitor. 
Subjects will self-administer the study drug on an outpatient basis once daily with or without 
food beginning on Day 1 (the day after the Baseline visit) and continue for 6 weeks (the last dose 
of study drug will be self-administered by the subject at home on the morning of Visit 6). 
Subjects will be instructed to administer study drug as a single oral dose in the morning at 
approximately the same time each day. Clinic visits are to begin no later than 6 hours postdose, if 
possible. 
During the baseline (Day -1) and treatment period (Days 1 to 42), subjects will have clinic visits 
at Days -1, 7, 14, and 28. In order to facilitate scheduling of clinic visits, a window of ± 2 days 
will be allowed for each clinic visit. Subjects will have a telephone contact at Day 35 (± 2). 
End of Treatment (EOT)/Early Termination (ET) (Day 42 [± 2]) 
Subjects will have a clinic visit at Day 42 for assessments of efficacy and safety. Subjects who 
discontinue the study prior to this visit will undergo the procedures and assessments for this visit 
at the time of discontinuation. 
Follow-up Period (Day 49 [± 2]) 
All subjects who received at least one dose of study drug will have a follow-up visit for safety 
and tolerability assessments 7 (± 2) days after their last study drug dose. Assessment of potential 
withdrawal effects will also be made during the follow-up period.  
Efficacy, Safety, and PK/PD Assessments 
Efficacy will be evaluated using the MADRS, CGI-BP-S, and HAM-A. Treatment response and 
symptom remission will be assessed using the MADRS. Additional assessments will include 
evaluation of functional impairment associated with bipolar depressive symptoms using the SDS 
total score and symptom severity using the QIDS-SR16 total score. 
Safety and tolerability will be monitored throughout the study by physical examinations, ECGs, 
vital signs, adverse event monitoring, clinical laboratory tests, YMRS, and C-SSRS. Subjects 
who have significant findings for suicidal ideation upon completion of the C-SSRS at any time 
during the study must be referred to the investigator for follow-up evaluation. Assessment of 
potential withdrawal effects will be conducted via administration of the Physician’s Withdrawal 
Checklist. Movement disorders will be assessed by AIMS, BARS, and SAS. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
31 
04 June 2018 
A Data and Safety Monitoring Board (DSMB) will review safety data at regular intervals during 
the study. 
Blood samples will be collected for population pharmacokinetics. Blood samples will be 
analyzed for plasma concentrations of R- and S-amisulpride and plasma prolactin. Prior to PK 
blood sample collection, subjects will record the date and time of their 3 most-recent study drug 
doses; the clinical site staff will record the dates and times of the 3 doses in the CRF (Visits 4 
and 6 only). Plasma samples collected for PK concentration analysis may also be used for the 
additional characterization and/or bioanalytical method development of putative metabolites of 
amisulpride and for other exploratory measurements, if needed. 
7.2. 
Treatment Assignment and Blinding 
7.2.1. 
Treatment Assignment 
After a subject provides consent, a unique subject number will be assigned at screening, 
consisting of a 3-digit protocol number, 3-digit site number, and a unique 3-digit subject 
identifier (eg, the second screened subject from site #005 will be 201005002). Subjects will be 
numbered consecutively. No subject numbers are to be reused once assigned. This number will 
track a subject throughout their participation in the study. 
Subjects who passed study entry criteria and did not get randomized can be rescreened once to 
determine eligibility. Subjects who are rescreened must be assigned a new screening number. 
Randomization will be stratified by region. The treatment schedule will be generated by a non-
study biostatistician. Once a subject is deemed eligible to be randomized at Day -1, an interactive 
voice/web-based system (IXRS) will perform the treatment assignment. Subjects will be 
randomized to 1 of 3 treatments in a 1:1:1 ratio: 
• SEP-4199 200 mg/day 
• SEP-4199 400 mg/day 
• Placebo QD 
7.2.2. 
Blinding 
Subjects, Investigators, clinical site staff, persons performing the assessments, clinical operations 
personnel (including the sponsor’s bioanalytical manager), data analysts, and personnel at central 
laboratories (including imaging) will remain blinded to the identity of the treatment from the 
time of randomization until unblinding, using the following methods: 
• Randomization data are kept strictly confidential until the time of unblinding, and 
will not be accessible by anyone else involved in the study with the following 
exceptions: bioanalytical laboratory personnel involved in the analysis of PK 
samples, DSMB members involved in regular review of safety data, external 
statistical staff involved in preparing materials for DSMB reviews, and the Sponsor’s 
clinical trials materials management. 
• Prolactin levels will be blinded except for results from Visit 1 (Screening). 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
32 
04 June 2018 
• The identity of the treatments will be concealed by the use of study drugs that are all 
identical in packaging, labeling, schedule of administration and appearance. 
• Study results, including unblinded data and randomization files, obtained in the US 
and Europe will not be published or disseminated to the Japan sites, Japan 
investigators or other personnel directly involved in the conduct of the study prior to 
the completion of the Japanese cohort. After unblinding of the US and Europe cohort, 
any personnel directly involved in the conduct of the US and Europe cohort will not 
be directly involved in the conduct of the Japanese cohort. 
Plasma concentrations of R-amisulpride, S-amisulpride, and total amisulpride will not be 
disclosed before unblinding of each cohort, respectively. In any case that concentration data 
transfer to the sponsor becomes necessary prior to the database lock, then the concentration data 
can only be shared with sponsor’s bioanalytical project manager with dummy subject IDs. 
7.2.3. 
Emergency Unblinding Procedures 
In the case of a medical emergency, where knowledge of study drug by the Investigator or an 
authorized delegate is essential for immediate medical management, a 24-hour code-break 
service will be available via the IXRS. The date and reason for unblinding are to be documented. 
Any subject for whom the treatment assignment was unblinded is to be discontinued from further 
study participation. The subject should return for a final study assessment as described in 
Section 11.6.4. The identity and responsibility of those individuals at the study site who gain 
access to the unblinded treatment assignment must be documented. It is mandatory that all 
personnel who are involved in the unblinding, and who have access to the unblinded treatment 
assignment, maintain the confidentiality of the information and do not divulge the treatment 
assignment. 
7.3. 
Rationale 
7.3.1. 
Rationale for the Dosages 
The enantiomers of amisulpride are stereoselective for 2 distinct therapeutic targets. The 
S-enantiomer is stereoselective for antagonism of dopamine D2 receptors. The R-enantiomer is 
stereoselective for antagonism of serotonin 5-HT7 receptors. 
In PET imaging of healthy volunteers, D2 occupancies below 50% are achieved following single 
doses of the S-enantiomer below 100 mg. In polysomnography of healthy volunteers, 
serotonergic effects (REM suppression) are achieved following single doses of the R-enantiomer 
at 340 mg and 600 mg. 
The ratio of 85:15 R:S-amisulpride (SEP-4199) is optimal for maximizing doses for serotonergic 
5-HT7 antagonism in a dose range which does not exceed 50% dopamine D2 occupancy. In 
PET imaging of healthy volunteers, D2 occupancies of 20-30% and 40-50% are achieved 
following single doses of 200 mg and 400 mg SEP-4199 (85:15), respectively. Thus, these fixed 
doses of SEP-4199 as a non-racemic 85:15 ratio will be utilized in this study. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
33 
04 June 2018 
7.3.2. 
Rationale for the Study Population 
The subject population includes males and females ranging from 18 to 65 years of age, and in 
concert with standard practice guidelines, will be required to have a diagnosis of bipolar I 
disorder, whose most recent episode is depressed with or without rapid cycling disease course 
(≥ 4 episodes of mood disturbance but < 8 episodes in the previous 12 months) with or without 
psychotic features (diagnosed by DSM-5 criteria, and confirmed by the SCID-5-CT). The current 
episode of major depression associated with bipolar I disorder will be confirmed by the 
Investigator and noted in the source records. 
7.3.3. 
Rationale for the Endpoints 
The efficacy assessments and their timing are considered appropriate to assess the efficacy of 
SEP-4199 in adults with bipolar I depression. The symptom, functional, and quality of life 
assessments were selected to address the potential effectiveness of SEP-4199 on these 
parameters. The standard safety assessments and their timing are appropriate to assess the safety 
of SEP-4199 in adults with bipolar I depression. 
7.4. 
Prevention of Missing Data 
In an effort to minimize the number of subjects who are terminated from the study before the end 
of treatment, the following study design and conduct elements are implemented: 
• Specific medications for the as needed (PRN) treatment of movement disorders and 
acute EPS are permitted. 
• Specific medications for the PRN treatment of anxiety/agitation and insomnia are 
permitted. 
• Training the sites on the importance of continued follow-up and on the informed 
consent process, ensuring subjects understand the commitment they are making, 
including the intent to complete the trial. 
• The Sponsor will use study centers with a good track record of enrolling and 
following eligible subjects. 
• Monitor data collection for adherence during the study. 
Refer to Section 15.3.9 for statistical considerations related to missing data. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
34 
04 June 2018 
8. 
SELECTION OF SUBJECTS 
8.1. 
Subject Inclusion Criteria 
To qualify for study participation, the subject must meet all of the following inclusion criteria: 
1. Subject is 18 to 65 years of age, inclusive, at the time of informed consent with bipolar I 
disorder, current episode depressed with or without rapid cycling disease course 
(≥ 4 episodes of mood disturbance but < 8 episodes in the previous 12 months) with or 
without psychotic features (diagnosed by DSM-5 criteria, and confirmed by the 
SCID-5-CT). The current episode of major depression associated with bipolar I disorder 
must be confirmed by the Investigator and noted in the source records. 
2. Subject provides written informed consent and is willing and able to comply with the 
protocol in the opinion of the investigator. 
3. Subject or legally acceptable representative must possess an educational level and degree 
of understanding of English or the local language that enables them to communicate 
suitably with the Investigator and the study coordinator. 
4. Subject must have a lifetime history of at least one bipolar manic or mixed manic 
episode. It is strongly recommended that a reliable informant (eg, family member or 
caregiver) be available to confirm this history. 
5. Subject’s current major depressive episode is ≥ 4 weeks and less than 12 months in 
duration at Screening. 
6. Subject has a MADRS total score ≥ 22 at both Screening and Baseline. 
7. Subject has a YMRS total score ≤ 12 at Screening. 
8. Female subjects of childbearing potential must have a negative serum ß-hCG test at 
Screening. 
9. Females who participate in this study must be one of the following: 
• Unable to become pregnant (eg, postmenopausal, surgically sterile, etc.) 
• Practicing abstinence or part of an abstinent lifestyle 
• Using and will continue to use a highly effective form of birth control for at least 
28 days prior to administration of the first dose of study drug, during the treatment 
period, and 2 months after completion or premature discontinuation from the study 
drug. See Section 10.4 for further information on acceptable methods of birth control. 
10. Male subjects with partners of child bearing potential must be practicing abstinence, part 
of an abstinent lifestyle or using protocol-specified methods of birth control. See 
Section 10.4 for further information on acceptable methods of birth control. 
11. Subject is in good physical health on the basis of medical history, physical examination, 
and laboratory screening. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
35 
04 June 2018 
12. Subjects with type 2 diabetes are eligible for study inclusion only if all of the following 
conditions are met within 30 days prior to Screening: 
• Subject’s random screening glucose is < 200 mg/dL (11.1 mmol/L). 
• Subject’s Hemoglobin A1c (HbA1c) ≤ 7.0%. 
• If a subject is currently being treated with oral anti-diabetic medication(s), the dose 
must have been stable for at least 30 days prior to screening. Such medication may be 
adjusted or discontinued during the study, as clinically indicated.  
• Subject has not required hospitalization for diabetes or related complications in the 
past 12 months. 
• Note: Subjects with type 2 diabetes that is newly diagnosed during screening are 
ineligible for the study. 
13. Subject who requires concomitant medication treatment with the following agents may be 
included if they have been on stable doses for the specified times: 1) oral hypoglycemics 
must be stabilized for at least 30 days prior to baseline; 2) thyroid hormone replacement 
must be stable for at least 90 days prior to baseline; 3) anti-hypertensive agents must be 
stable for at least 30 days prior to baseline. The subject’s medical condition should be 
deemed clinically stable following consultation with the Medical Monitor as needed. 
8.2. 
Subject Exclusion Criteria 
The subjects who meet any of the following criteria will be excluded in the study. 
1. Subject has a lifelong history or presence of symptoms consistent with a major 
psychiatric disorder other than bipolar I disorder as defined by DSM-5. Exclusionary 
disorders include but are not limited to moderate to severe alcohol use disorder (within 
past 12 months), substance use disorder (other than nicotine or caffeine) within past 
12 months, bipolar II disorder, schizoaffective disorder, obsessive compulsive disorder, 
posttraumatic stress disorder. 
2. Subject demonstrates a decrease (improvement) of ≥ 25% in MADRS total score from 
Screening to Baseline, or subject’s MADRS total score is < 22 at Baseline. 
3. Subject has received treatment with antidepressants within 3 days of randomization, 
fluoxetine at any time within 28 days, an MAO inhibitor within 21 days or clozapine 
within 120 days. All other psychotropic medications with the exceptions of lorazepam, 
temazepam, eszopiclone, zopiclone, zolpidem and zolpidem CR require 3 days minimum 
washout (see Section 10.3.3 for lorazepam, eszopiclone, zopiclone, temazepam, 
zolpidem, and zolpidem CR treatment restrictions). Depot neuroleptics must be 
discontinued at least one treatment cycle prior to randomization. 
4. Subject has suspected/confirmed Borderline Personality Disorder. 
5. Subject currently has a clinically significant neurological, metabolic (including 
type 1 diabetes), hepatic, renal, hematological, pulmonary, cardiovascular, 
gastrointestinal, and/or urological disorder such as unstable angina, congestive heart 
failure (uncontrolled), or central nervous system (CNS) infection that would pose a risk 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
36 
04 June 2018 
to the subject if they were to participate in the study or that might confound the results of 
the study. Subjects with a known history of HIV seropositivity will be excluded. 
 
Note: Active medical conditions that are minor or well-controlled are not exclusionary if 
they do not affect risk to the subject or the study results. In cases in which the impact of 
the condition upon risk to the subject or study results is unclear, the Medical Monitor 
should be consulted. Any subject with a known cardiovascular disease or condition (even 
if under control) must be discussed with the Medical Monitor before being randomized in 
the study. 
6. Subject has evidence of any chronic organic disease of the CNS such as tumors, 
inflammation, active (or history of) seizure disorder, vascular disorder, Parkinson’s 
disease, Alzheimer’s disease or other forms of dementia, myasthenia gravis, or other 
degenerative processes. In addition, subjects must not have a history of intellectual 
disability or persistent neurological symptoms attributable to serious head injury. Past 
history of febrile seizure, is not exclusionary. 
7. Subject has a history of malignancy < 5 years prior to signing the informed consent, 
except for adequately treated basal cell or squamous cell skin cancer or in situ cervical 
cancer. Subjects with pituitary tumors of any duration are excluded. 
8. Subject demonstrates evidence of acute hepatitis, clinically significant chronic hepatitis, 
or evidence of clinically significant impaired hepatic function through clinical and 
laboratory evaluation (use screening values for laboratory evaluation). Subject has a 
history of stomach or intestinal surgery or any other condition that could interfere with 
absorption, distribution, metabolism, or excretion of medications. 
9. Subject has knowledge of any kind of cardiovascular disorder/condition known to 
increase the possibility of QT prolongation or history of additional risk factors for torsade 
de pointes (eg, heart failure, hypokalemia, family history of Long QT Syndrome or 
Brugada Syndrome) or cardiac conduction disorders, or requires treatment with an 
antiarrhythmic medication. 
10. Subject has family history of QTc prolongation or of unexplainable sudden death at 
< 50 years of age. 
11. Abnormal 12-lead ECG at Screening, including: 
• QTcF > 450 ms (male subjects) or > 470 ms (female subjects) 
• QRS > 110 ms 
• PR > 200 ms 
• Second- or third-degree atrioventricular block 
• Any rhythm other than sinus rhythm, which is interpreted by the Investigator to be 
clinically significant 
12. Subject has a history of neuroleptic malignant syndrome (NMS). 
13. Subject exhibits evidence of severe tardive dyskinesia, severe dystonia, or any other 
severe movement disorder. Severity is to be determined by the investigator. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
37 
04 June 2018 
14. Subject has been diagnosed with type 1 diabetes, or insulin-dependent diabetics. 
15. Subject who has any abnormal laboratory parameter at screening that indicates a 
clinically significant medical condition as determined by the investigator. 
• Subjects with fasting blood glucose at screening ≥ 126 mg/dL (7.0 mmol/L) will be 
excluded from the study. 
• Subjects with fasting blood glucose from 100-125 mg/dL (5.6-6.9 mmol/L) may enter 
the study based on the approval of the Medical Monitor. 
• Subjects who are found to have been non-fasting at Screening may be allowed if their 
blood glucose is < 200 mg/dL. Subjects with random (nonfasting) blood glucose at 
screening ≥ 200 mg/dL (11.1 mmol/L) must be retested in a fasted state. 
• Subjects with HbA1c > 7.0% will be excluded. 
16. Subject has a prolactin concentration > 100 ng/mL at screening or have a history of 
pituitary adenoma. 
17. Subject has a body mass index (BMI) ≥ 40 or < 18 kg/m2 at Screening. 
18. Subject has a history of non-response to an adequate (6-week) trial of three or more 
antidepressants (with or without mood stabilizers) during the current episode. 
19. Subject is considered by the Investigator to be at imminent risk of suicide or injury to 
self, others, or answers “yes” to “Suicidal Ideation” item 4 (active suicidal ideation with 
some intent to act, without specific plan) or item 5 (active suicidal ideation with specific 
plan and intent) on the C-SSRS assessment at the Screening visit (in the past month 
[30 days]) or Baseline. 
20. Subject tests positive for drugs of abuse at screening or baseline. In the event a subject 
tests positive for cannabinoids (tetrahydrocannabinol), the investigator will evaluate the 
subject’s ability to abstain from cannabis during the study. This information will be 
discussed with the Medical Monitor for study enrollment consideration. 
21. Subject has a history of hypersensitivity to more than two distinct chemical classes of 
drug (eg, sulfas and penicillins). 
22. Subjects have received depot neuroleptics unless the last injection was at least one 
treatment cycle before randomization. 
23. Subject requires treatment with a drug that consistently prolongs the QTc interval (see 
Section 23, Appendix IV). 
24. Subject has received ECT within 90 days prior to randomization or is expected to require 
ECT during the study course. 
25. Subject is currently participating, or has participated in a study with an investigational or 
marketed compound or device within 6 months prior to signing the informed consent, or 
has participated in 3 or more studies within 18 months prior to signing the informed 
consent. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
38 
04 June 2018 
9. 
STUDY DRUG MATERIALS AND MANAGEMENT 
9.1. 
Description of Study Drug 
SEP-4199 will be supplied as matching 100 mg and 200 mg tablets each containing a fixed ratio 
of 85:15 (R-amisulpride:S-amisulpride). Two 100 mg tablets will be given for the 200 mg dose. 
Two 200 mg tablets will be given for the 400 mg dose. Two placebo tablets matching SEP-4199 
active tablets will be given for the placebo dose. 
Table 5: 
Investigational Product 
Attribute 
Investigational Product 
Product name 
SEP-4199 100 mg 
SEP-4199 200 mg 
Matching Placebo 
Dosage form 
Tablets 
Tablets 
Tablets 
Unit dose 
Tablet 
Tablet 
Tablet 
Route of administration 
Oral 
Oral 
Oral 
Physical description 
Pale orange oval 
film-coated 
unmarked tablets 
Pale orange oval 
film-coated 
unmarked tablets 
Pale orange oval 
film-coated 
unmarked tablets 
Excipients 
D-Mannitol, pregelatinized starch, croscarmellose sodium, 
polyvinyl alcohol, magnesium stearate, hydroxypropyl 
methylcellulose, Macrogol 400, titanium dioxide, talc, iron oxide 
yellow, iron oxide red, carnauba wax 
9.2. 
Study Drug Packaging and Labeling 
9.2.1. 
Package Description 
Study drug will be provided in one-week blister cards containing 18 oral tablets of SEP-4199 
100 mg, 200 mg, or Placebo tablets (7 days + 2 extra days). 
9.2.2. 
Labeling Description 
All labeling and packaging for study drug will be based on all applicable regulatory requirements 
described in either United States (US) Code of Federal Regulations (CFR), CFR21, Part 312.6, 
Annex 13 of “The Rules Governing Medicinal Products in the European Community, Volume 4 
Good Manufacturing Practice for Medicinal Products,” and/or in accordance with any other local 
applicable regulatory requirements. Label text may include, but are not limited to, the following 
information: 
• Protocol number 
• Sponsor’s name and address 
• Compound/Code or name of investigational drug (if needed) 
• Contents (eg number of tablets, strength) 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
39 
04 June 2018 
• Investigational Drug/caution statement or New Drug statement 
• Instructions for use and storage 
• Blank space for study center number and date opened (if needed) 
• Lot number 
• Randomization number (if needed) 
• Expiration date (if needed) 
• Visit number (of needed) 
• Unique medication number (if needed) 
• Space for subject identifiers (if needed) 
• Investigator information (if needed) 
9.3. 
Study Drug Storage 
SEP-4199 tablets and placebo tablets are to be stored between 15°C and 25°C (59°F and 77°F); 
excursions are permitted to 30°C (86°F), and away from light. The study drug storage area will 
be monitored for temperature. The subject will be instructed to store the medication at room 
temperature. 
9.4. 
Dispensing of Study Drug 
An IXRS will be used to manage subject screening and randomization, drug dispensation and 
accountability. The IXRS is an integrated web-based subject and drug management system. 
Study drug blister cards will be assigned by the IXRS based on the treatment schedule. The 
IXRS will generate instructions for which study medication unit/number to assign to a subject. 
Each subject will be dispensed one or two 9-day blister cards per scheduled visit, depending on 
the timing of the next scheduled visit (see Table 2). 
The first study drug dose will be taken on Day 1. Subjects will be instructed to take their study 
drug as a single oral dose once a day in the morning at approximately the same time each day. 
Study visits will begin no later than 6 hours postdose, if possible. Study drug may be taken with 
or without food. Clinical site staff will interview the subject for self-report of the last 3 doses and 
record the date and time of each study drug administration in the source (all visits) and CRF 
(Visits 4 and 6 only). 
Study drug should be maintained under the strict control of qualified site staff at all times. 
Appropriate guidelines should be followed in proper dispensation to the study participant. Proper 
handling and storage should be followed. IXRS drug dispensing guidelines should be followed 
for dispensing study drug to the subject, in addition to all accountability records where required. 
Specific User Manuals will be supplied. 
9.5. 
Study Drug Accountability 
The Investigator or designee is responsible for storing the drug in a secure location and for 
maintaining adequate records of drug disposition that includes the dates, quantity, and use by 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
40 
04 June 2018 
subjects. If the study is stopped for any reason or completed, all unused supplies of drug will be 
returned to the Sponsor, unless other instructions are provided in writing by Sponsor/CRO. 
Upon receipt of study drug, the Investigator or designee will inventory the supplies and verify 
receipt of supplies. The site will perform an acknowledgement of receipt via the IXRS, 
confirming the date of receipt, inventory and condition of study drug received. 
The IXRS will be used for the accountability of the study drug at the clinical site. The 
Investigator or designee will maintain the inventory for accountability within the IXRS, 
including study drug dispensation, return and availability of study drug received. The 
Investigator or designee will collect and document all used and unused study drug from study 
subjects at appropriate study visits. 
The drug will not be dispensed to any person who is not a study subject under this protocol. 
Study drug will not be dispensed to any subject following the completion of the 6-week 
treatment period.  
9.6. 
Study Drug Handling and Disposal 
A drug inventory record will be supplied from Sponsor/CRO. The Investigator or designee on an 
ongoing basis must maintain a drug inventory record of supplied, received, dispensed, and 
returned medication. The Investigator or designee is required to return all unused study drug to 
the Sponsor or designee as instructed. The Investigator or designee is required to maintain copies 
of medication shipping receipts, drug accountability records, and records of return or final 
disposal of the study drug in accordance with local regulatory requirements. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
41 
04 June 2018 
10. 
TREATMENT OF SUBJECTS 
10.1. 
Study Drug 
SEP-4199 100 mg and 200 mg tablets for 200 mg and 400 mg doses will be supplied as 
described in Section 9.1. 
Study drug tablets will be self-administered by the subject once daily as a single oral dose in the 
morning at approximately the same time, beginning on Day 1 and continuing through Visit 6 
(Day 42 ± 2). 
10.2. 
Treatment Compliance 
Subjects will self-report the date and time of their last 3 doses prior to each clinic visit. Site staff 
will record these last 3 dosing times in the CRF for Visits 4 and 6 and returned drug 
accountability details in IXRS for each dispensed kit upon return by subject. 
10.3. 
Prior and Concomitant Medications and Therapies 
The following information on all concomitant medication administered between Visit 1 and 
Visit 7 or at discontinuation will be recorded on the CRF: Medication name, dose, frequency, 
route, start date, stop date, and indication. 
Information on the format and version of coding dictionary is provided in the Data Management 
Plan (DMP). All medications will be coded using WHO-DD. 
Initiation of new psychotherapeutic interventions (e.g., a new course of psychotherapy) will not 
be permitted during the study. Subjects who have participated in ongoing psychotherapy 
treatment for at least 12 weeks prior to screening will be permitted to continue this treatment 
during the study. 
Any medication or non-pharmacological therapy that is taken by or administered to the subject at 
any point during the course of this study must be recorded in the eCRF. The entry must include 
the dose, regimen, route, indication, and dates of use. 
10.3.1. 
Prior Medications 
Treatment with all prior psychotropic medications (eg, antipsychotic agents, antidepressants, and 
mood stabilizers) must be discontinued as tolerated and clinically appropriate at least 3 days or 
5 half-lives (whichever is longer) prior to randomization. Treatment with sedative hypnotics (for 
insomnia) is permitted during the screening period, but should be tapered as clinically 
appropriate to conform with and adequately prepare the subject for the protocol-specified dosing 
limitations applicable to these agents following randomization (see Section 10.3.3). Subjects 
treated with fluoxetine, or olanzapine plus fluoxetine combination must discontinue these 
medications at least 28 days prior to randomization. Depot neuroleptics must be discontinued at 
least one treatment cycle prior to randomization. Subjects treated with MAO inhibitors must 
discontinue these medications at least 21 days prior to randomization. All other psychotropic 
medication (except as described in this section), including medication and herbal supplements 
(eg, Gingko Biloba, Kava Kava, St. John’s Wort) must be discontinued as tolerated and clinically 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
42 
04 June 2018 
appropriate prior to randomization. Subjects should not be taken off their current effective 
medications for treatment of bipolar depression for purposes of participating in this protocol. 
10.3.2. 
Concomitant Nonpsychotropic Medications 
Non-psychotropic medications used to treat mild, chronic medical conditions may be used during 
screening and after randomization if the dose and regimen have been stable (± 25%) for at least 
30 days prior to screening. The concomitant medication dose may change as needed after 
randomization (or be discontinued). Routine vaccines (ie, seasonal influenza, pneumonia, etc.) 
are allowed based on Investigator judgement. β-adrenergic antagonists used to treat stable 
hypertension may be continued through the screening/washout phase and post-randomization. In 
addition, use of non-prescription pain medications (e.g., aspirin, acetaminophen/paracetamol, 
ibuprofen) is allowed during all phases of the study provided these medications do not have a 
propensity for psychotropic effects and do not interfere with the evaluation of study medication. 
Medications for short-term treatment of a medical condition (no more than 10 days) are allowed 
without consultation with the Medical Monitor provided that the medications do not consistently 
prolong the QTc interval (see Section 23, Appendix IV). 
10.3.3. 
Concomitant Psychotropic/Antipsychotic Medications 
Treatment with benztropine (up to 6 mg/day) will be permitted as needed for movement 
disorders. In cases where benztropine is not available or a subject has had an inadequate response 
or intolerability to benztropine treatment, the following medications may be used to treat acute 
EPS: biperiden (up to 16 mg/day) or trihexyphenidyl (up to 15 mg/day) or diphenhydramine 
(up to 100 mg/day). Treatment with propranolol (up to 120 mg/day) or amantadine (up to 
300 mg/day) will be permitted as needed for akathisia. These allowed medications for the 
treatment of EPS, akathisia, and dystonia may be given in any formulation (oral, IM, or IV) as 
deemed appropriate by the investigator. Medications used to treat movement disorders should 
not be given prophylactically. Medications used for movement disorders should be tapered and 
discontinued prior to randomization but may be reinstituted if symptoms emerge. 
In situations where anticholinergic agents or sedative/hypnotic agents (or any agents that may 
cause sedation) are administered, these should be taken at the same time each day and should not 
be taken within 8 hours of scheduled assessments. In regions that do not have the specified drugs 
available, similar drugs at equivalent dosages will be substituted as described in the Study 
Reference Manual or in consultation with the Medical Monitor. 
Concomitant use of sedative hypnotics is permitted during Screening and for Weeks 1-3 (through 
Visit 5) at the discretion of the Investigator with the following restrictions: Lorazepam is 
permitted at the discretion of the Investigator up to 2 mg/day for intolerable anxiety/agitation, as 
clinically indicated. Lorazepam should be used sparingly, when clinically required, per 
investigator judgment. Lorazepam (≤ 2 mg/day), eszopiclone (≤ 3 mg/day), zopiclone 
≤ 7.5 mg/day), zolpidem (≤ 10 mg/day), zolpidem CR (≤ 12.5 mg/day) and temazepam 
(≤ 30 mg/day) may be administered at bedtime for insomnia, as needed. Hypnotic agents should 
be administered no more than once nightly and should not be used in combination. Continued 
use of the above sedative hypnotics beyond Visit 5 requires approval from the Medical Monitor. 
Anxiolytics, sedatives or hypnotics should not be administered within 8 hours prior to any 
psychiatric assessments. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
43 
04 June 2018 
In regions where lorazepam or zolpidem or other specified medications are not available, another 
similar agent at equivalent doses will be permitted as specified by the Medical Monitor and/or 
the Study Reference Manual. Opiates may be allowed in rare cases for a limited period of time 
with prior authorization from the Medical Monitor. 
Subjects who require treatment with one or more of the restricted medications should be 
excluded or discontinued (as appropriate) from the study. Since the list of medications in 
Section 23, Appendix IV is not comprehensive, the Investigator should use medical judgment 
when a subject presents with a medication not on the list or consult with the Medical Monitor for 
clarification. 
10.3.4. 
Prohibited Medications 
Treatment with all psychotropic medications (eg, antipsychotic agents, antidepressants, and 
mood stabilizers) must be discontinued as tolerated and clinically appropriate at least 3 days or 
5 half-lives prior to randomization, whichever is longer. Subjects treated with fluoxetine or 
olanzapine plus fluoxetine combination must have discontinued these medications at least 
28 days prior to randomization. Depot neuroleptics must have been discontinued at least one 
treatment cycle prior to randomization. Subjects treated with MAO inhibitors must have 
discontinued these medications at least 21 days prior to randomization. 
Treatment with sedative hypnotics (for insomnia) is permitted during the screening period, but 
should be tapered as clinically appropriate to ensure the subject meets and can comply with the 
protocol-specified dosing limitations applicable to these agents following randomization (see 
Section 10.3.3). 
Medications that consistently prolong the QTc interval are prohibited during the study. For a list 
of these medications, please see Section 23, Appendix IV. 
The use of herbal supplements for any reason is prohibited during trial participation. The use of 
dietary supplements (eg, omega fatty acids) or other complementary or alternative medications 
for treating depression during the trial is not permitted. 
With the exception of benztropine, biperiden, trihexyphenidyl, and diphenhydramine (or their 
equivalent as agreed by the Medical Monitor) as specified in Section 10.3.3, medications used to 
treat movement disorders (including levodopa) are prohibited. 
10.4. 
Contraception Requirements 
Female Subjects 
1. Female subjects of childbearing potential must be using and willing to continue using a 
highly effective form of birth control for at least 28 days prior to administration of the 
first dose of study drug, during the treatment period, and 2 months (60 days) after 
completion or premature discontinuation from the study drug. Highly effective forms of 
contraception include: 
• Combined estrogen and progestogen containing hormonal contraception (oral, 
intravaginal or transdermal) associated with inhibition of ovulation. 
• Progestogen-only hormonal contraception (oral, injectable, implantable) associated 
with inhibition of ovulation. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
44 
04 June 2018 
• Intrauterine device. 
• Intrauterine hormone-releasing system. 
• Bilateral tubal occlusion. 
• Male sterilization (with the appropriate post-vasectomy documentation of the absence 
of sperm in the ejaculate). For female subjects on the study, the vasectomized male 
partner should be the sole partner for that subject. 
• True abstinence: When this is in line with the preferred and usual lifestyle of the 
subject. Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation 
methods) and withdrawal are not acceptable methods of contraception. 
Women using hormonal contraception must use an additional form of contraception (eg, condom 
with spermicide). Because of the unacceptable failure rate of barrier (chemical and/or physical) 
methods, the barrier method of contraception must only be used in combination with a highly 
effective method. Post-coital methods of contraception are not permitted. The following is 
required: 
2. A female subject is eligible to enter and participate in the study if she is of: 
a. Non-childbearing potential (ie, physiologically incapable of becoming pregnant, 
including any female who is pre-menarchal or post-menopausal); 
− Postmenopausal females defined as being amenorrheic for greater than 2 years (or 
confirmed by FSH level) with an appropriate clinical profile. 
− Women who have had a hysterectomy, bilateral oophorectomy or bilateral 
salpingectomy (as determined by subject’s medical history). 
− Women who have not been confirmed as postmenopausal and are not surgically 
sterile should be advised to use contraception as outlined above under number 1. 
b. Childbearing potential, has a negative pregnancy test at screening and agrees to 
satisfy one of the following requirements: 
− Complete abstinence from intercourse (as part of an abstinent lifestyle) a 
minimum of 2 months (60 days) prior to administration of the first dose of study 
drug, throughout the Treatment Period, and for a minimum of 3 months (90 days) 
after completion or premature discontinuation from the study drug; or, 
− Established use of highly effective methods of contraception from 28 days prior to 
administration of the first dose of study drug, during the Treatment Period, and 
2 months (60 days) after completion or premature discontinuation from the study 
drug. Highly effective methods of birth control are listed above in number 1). 
Male Subjects 
Male subject with female partner(s) of childbearing potential must ensure that their partner(s) 
uses the methods of contraception as outlined for female subjects above. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
45 
04 June 2018 
10.5. 
Guidance for Overdose 
The effects of an overdose of SEP-4199 are unknown and there is no known treatment in case of 
overdose. Standard symptom support measures should be used in the case of excessive 
pharmacological effects or overdose. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
46 
04 June 2018 
11. 
STUDY ASSESSMENTS 
A study schematic is presented in Figure 1. A summary of assessments to be conducted at each 
visit is presented in Table 2. 
Study drug should be administered once daily in the morning at approximately the same time 
each day. 
11.1. 
Demographics and Baseline Characteristics 
Subject self-report will be acceptable for listing all prior and concomitant medication use, 
demographics, medical history, psychiatric history, and evaluation for inclusion/exclusion except 
where specific protocol procedures are mandated to ensure appropriate enrollment (eg, certain 
baseline laboratory values). All medications taken within the 30 days before screening will be 
recorded. 
Demographics collected at screening will include sex, race, ethnicity, date of birth, weight, and 
height, as allowed per region. 
Clinical site staff will calculate and record BMI at screening. BMI for all other visits will be 
calculated in the analyses. 
Waist circumference will be measured in inches or centimeters and recorded in the CRF. 
For medical history, only relevant/significant medical history and recurrence of any condition 
will be collected. 
11.2. 
Diagnostic Scales to Determine Study Eligibility 
11.2.1. 
SCID-5-CT 
The Structured Clinical Interview for DSM-5 (SCID-5) is the most widely used structured 
diagnostic instrument for assessing DSM-5 disorders. The SCID-5 is organized into diagnostic 
modules, and it assesses mood disorders, psychotic disorders, substance use disorders, anxiety 
disorders, obsessive–compulsive and related disorders, eating disorders, somatic symptom 
disorders, some sleep disorders (i.e., insomnia and hypersomnolence disorders), “externalizing 
disorders” (ie, intermittent explosive disorder, gambling disorder, and adult attention deficit 
hyperactivity disorder), and trauma- and stressor-related disorders. The SCID-5-CT for clinical 
trials (SCID-CT; First 2015) will be utilized to confirm the diagnosis of bipolar I depression for 
this study. 
The SCID-5-CT will be administered by a qualified rater at the site. Further information 
regarding administration of the SCID-5-CT to determine study eligibility will be provided in the 
Study Reference Manual. 
11.2.2. 
Young Mania Rating Scale (YMRS) 
The YMRS will be administered at Screening and Baseline to determine subject eligibility. 
Subjects must have a YMRS total score ≤ 12 at both the Screening and Baseline visits. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
47 
04 June 2018 
The YMRS is an 11-item instrument used to assess the severity of mania in patients with a 
diagnosis of bipolar disorder. The 11 items are: Elevated Mood, Increased Motor Activity 
Energy, Sexual Interest, Sleep, Irritability, Speech (Rate and Amount), Language-Thought 
Disorder, Content, Disruptive-Aggressive Behaviour, Appearance and Insight. The YMRS is 
a clinician-rated assessment. YMRS uses operationally defined anchor points and the normal 
expected score is > 20. Ratings are based on patient self-reporting, combined with clinician 
observation (accorded greater score). 
The YMRS will be administered by a qualified rater at the site. Further information regarding 
administration of the YMRS, including rater training and certification as well as recording 
YMRS scores to determine study eligibility will be provided in the Study Reference Manual. 
11.2.3. 
Montgomery-Asberg Depression Rating Scale (MADRS) 
The MADRS will be administered at Screening and Baseline to determine subject eligibility. To 
be eligible for enrollment, subjects must have a MADRS total score ≥ 22 at Screening. Subjects 
who have a decrease (improvement) of ≥ 25% in MADRS total score from Screening to 
Baseline, or who have a MADRS total score < 22 at Baseline will not be eligible for study 
participation (see Section 24, Appendix V). 
The MADRS is a clinician-rated assessment of the subject’s level of depression. The measure 
contains 10 items that measure apparent and reported sadness, inner tension, reduced sleep and 
appetite, difficulty concentrating, lassitude, inability to feel, and pessimistic and suicidal 
thoughts. Each item is scored in a range of 0 to 6 points, with higher scores indicating increased 
depressive symptoms. The Structured Interview Guide for the MADRS (SIGMA) will be used 
for the administration of the MADRS assessment. 
Further information regarding administration of the MADRS, including rater training and 
certification as well as recording MADRS scores will be provided in the Study Reference 
Manual. 
11.3. 
Efficacy Assessments 
11.3.1. 
Montgomery-Asberg Depression Rating Scale (MADRS) 
In addition to administration of the MADRS at Screening and Baseline to determine subject 
eligibility, the MADRS will be administered at post-baseline visits as an efficacy assessment. 
The MADRS is a clinician-rated assessment of the subject’s level of depression. The measure 
contains 10 items that measure apparent and reported sadness, inner tension, reduced sleep and 
appetite, difficulty concentrating, lassitude, inability to feel, and pessimistic and suicidal 
thoughts. Each item is scored in a range of 0 to 6 points, with higher scores indicating increased 
depressive symptoms. The Structured Interview Guide for the MADRS (SIGMA) will be used 
for the administration of the MADRS assessment. 
Further information regarding administration of the MADRS, including rater training and 
certification as well as recording MADRS scores will be provided in the Study Reference 
Manual. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
48 
04 June 2018 
11.3.2. 
Clinical Global Impressions – Severity: Bipolar Version 
(CGI-BP-S - Depression) 
The CGI-BP-S is a clinician-rated assessment of the subject’s current illness state on a 7-point 
scale, where a higher score is associated with greater illness severity. Following a clinical 
interview, the CGI-BP-S can be completed in 1-2 minutes. 
Further information regarding administration of the CGI-BP-S, including rater training and 
certification as well as recording CGI-BP-S scores will be provided in the Study Reference 
Manual. 
11.3.3. 
Hamilton Rating Scale for Anxiety (HAM-A) 
The HAM-A is a rating scale developed to quantify the severity of anxiety symptomatology. It 
consists of 14 items, each defined by a series of symptoms. Each item is rated on a 5-point scale, 
ranging from 0 (not present) to 4 (severe/disabling). The Structured Interview Guide for the 
HAM-A (SIGH-A) will be used for the administration of the HAM-A. 
Further information regarding administration of the HAM-A, including rater training and 
certification as well as recording HAM-A scores will be provided in the Study Reference 
Manual. 
11.3.4. 
Sheehan Disability Scale (SDS) 
The SDS is a composite of three items designed to measure the extent to which three major 
sectors in the patient’s life are impaired by depressive symptoms. This anchored visual analog 
scale uses spatiovisual, numeric, and verbal descriptive anchors simultaneously to assess 
disability across three domains: work, social life, and family life. The patient rates the extent to 
which his or her 1) work, 2) social life or leisure activities, and 3) home life or family 
responsibilities are impaired by his or her symptoms on an 11-point visual analogue scale 
ranging from 0 to 10. There are verbal descriptors for the points on the scale as well as numerical 
scores that provide more precise levels of the verbal descriptors. The three items may be summed 
into a single dimensional measure of global functional impairment that ranges from 
0 (unimpaired) to 30 (highly impaired). 
Further information regarding administration of the SDS, including rater training and 
certification as well as recording SDS scores will be provided in the Study Reference Manual. 
11.3.5. 
Quick Inventory of Depressive Symptomatology – Self-Report 16-Item 
(QIDS-SR16) 
The QIDS-SR16 is a 16-item self-report measure of depressive symptomatology which uses a 
computerized assessment interface for administration. The scoring system for the QIDS-SR16 
converts responses to 16 separate items into the nine DSM-IV symptom criterion domains. The 
total score ranges from 0 to 27. The nine domains comprise: sad mood; concentration; 
self-criticism; suicidal ideation; interest; energy/fatigue; sleep disturbance (initial, middle, and 
late insomnia or hypersomnia); decrease/increase in appetite/weight; and psychomotor 
agitation/retardation. Site staff will assist the subject in the initiation of the QIDS-SR16 
assessment, which will take place at the site. Clinical site staff will not participate in the 
administration of the QIDS-SR16 after initiation. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
49 
04 June 2018 
Further information regarding administration of the QIDS-SR16, including recording scores will 
be provided in the Study Reference Manual. 
11.3.6. 
EuroQoL 5-D (EQ-5D-5L) 
The EQ-5D-5L is a standardized instrument developed by the EuroQoL Group as a measure of 
health-related quality of life that can be used in a wide range of health conditions and treatments. 
The EQ-5D-5L consists of a descriptive system and the EQ VAS. 
The descriptive system comprises five dimensions: mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight 
problems, moderate problems, severe problems and extreme problems. The patient is asked to 
indicate his/her health state by ticking the box next to the most appropriate statement in each of 
the five dimensions. This decision results in a 1-digit number that expresses the level selected for 
that dimension. The digits for the five dimensions can be combined into a 5-digit number that 
describes the patient’s health state. 
The EQ VAS records the patient’s self-rated health on a vertical visual analogue scale, where the 
endpoints are labelled ‘The best health you can imagine’ and ‘The worst health you can imagine’. 
The VAS can be used as a quantitative measure of health outcome that reflect the patient’s own 
judgement. 
11.4. 
Safety Assessments 
The Investigator or appropriate designee will review results of safety assessments as they 
become available. The Sponsor must be kept fully informed of any clinically significant findings 
either at Screening or subsequently during study conduct through appropriate adverse event 
reporting and/or escalation to the Medical Monitor. 
11.4.1. 
Pretreatment Events and Adverse Events 
Pretreatment events will be recorded from the time informed consent is provided at screening 
until the time of first dose administration at Day 1. 
Adverse events will be collected for each subject. Subjects should be queried in a non-leading 
manner, without specific prompting (eg, “Has there been any change in your health status since 
your last visit?”). See Section 12, Safety Reporting. 
AEs and SAEs will be monitored throughout the study at all visits. 
11.4.2. 
Clinical Laboratory Tests 
The clinical laboratory tests required by protocol are listed in Section 21, Appendix II. 
Blood and urine samples will be collected for clinical laboratory tests. All clinical laboratory 
tests will be performed centrally. For detailed instructions regarding clinical laboratory 
procedures, sampling, and shipping guidelines refer to the Central Laboratory Instructions 
Manual. Samples will be processed at a central laboratory to ensure consistency. All clinical 
laboratories will be College of American Pathologists (CAP) and Clinical Laboratory 
Improvement Amendments (CLIA) (or equivalent) certified. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
50 
04 June 2018 
To determine subject eligibility, abnormal Screening clinical laboratory tests may only be 
repeated after discussion with the Medical Monitor. 
11.4.3. 
Vital Signs 
Supine systolic and diastolic blood pressures, respiratory rate, pulse rate, and temperature will be 
measured. 
After being in a supine position for ≥ 5 minutes, systolic and diastolic blood pressures, 
respiratory rate, pulse rate, and temperature will be collected. Blood pressure and pulse rate will 
be taken again after standing for 2 to 4 minutes. The same arm should be used during each 
assessment of blood pressure and pulse rate throughout the study. 
If a subject develops symptoms consistent with orthostatic hypotension (light-headedness, 
dizziness, or changes in sensorium upon standing) at any point, his or her supine and standing 
blood pressure and pulse rate should be collected at that time in the manner described above. 
11.4.4. 
Centrally-read ECG 
All ECGs will be obtained in the supine position, after the subject has been resting supine for at 
least 5 minutes. ECGs will be 12-lead with a 10-second rhythm strip. ECGs should be obtained 
prior to drawing blood samples, with the exception of fasting blood draws. All attempts should 
be made to use the same ECG recorder for all visits within individual subjects. ECGs will be 
centrally read at a core lab according to established quality assurance procedures for inter/intra 
reader variability. Refer to Section 20, Appendix I for additional information. 
To determine subject eligibility, Screening ECG may only be repeated due to technical issues. 
11.4.5. 
Safety Scales 
11.4.5.1. Columbia-Suicide Severity Rating Scale (C-SSRS) 
The C-SSRS is a tool designed to systematically assess and track suicidal AEs (suicidal behavior 
and suicidal ideation) throughout the study. The strength of this suicide classification system is 
in its ability to comprehensively identify suicidal events while limiting the over-identification of 
suicidal behavior. The C-SSRS will be administered by a trained rater at the site. 
This study will utilize 2 versions of the C-SSRS. At the screening visit, the baseline/screening 
version will be completed; for all subsequent visits, the “Since Last Visit” version of the C-SSRS 
will be administered. 
Subjects who answer “yes” to “suicidal ideation” item 4 (active suicidal ideation with some 
intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and 
intent) on the C-SSRS assessment at Screening (in the past month) are not eligible and must be 
referred to the Investigator for follow-up evaluation. 
Further information regarding administration of the C-SSRS, including rater training and 
certification as well as recording C-SSRS scores will be provided in the Study Reference 
Manual. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
51 
04 June 2018 
11.4.5.2. Young Mania Rating Scale (YMRS) 
In addition to administration of the YMRS at Screening and Baseline to determine subject 
eligibility, the YMRS will be administered at post-baseline visits as an efficacy assessment. 
The YMRS is an 11-item instrument used to assess the severity of mania in patients with a 
diagnosis of bipolar disorder. The 11 items are: Elevated Mood, Increased Motor Activity 
Energy, Sexual Interest, Sleep, Irritability, Speech (Rate and Amount), Language-Thought 
Disorder, Content, Disruptive-Aggressive Behaviour, Appearance and Insight. The YMRS is a 
clinician-rated assessment. YMRS uses operationally-defined anchor points and the normal 
expected score is > 20. Ratings are based on patient self-reporting, combined with clinician 
observation (accorded greater score). 
Further information regarding administration of the YMRS, including rater training and 
certification as well as recording YMRS scores will be provided in the Study Reference Manual. 
11.4.5.3. Abnormal Involuntary Movement Scale (AIMS) 
The AIMS is a clinician-rated assessment of abnormal movements consisting of unobtrusive 
observation of the subject at rest (with shoes removed) and several questions or instructions 
directed toward the subject. Using a severity scale ranging from 0 (none) to 4 (severe), clinicians 
rate dyskinesia in several body regions, including the facial area, extremities, and trunk. There 
are two items related to dental status, as well as three global impression items assessing overall 
severity, incapacitation, and the subject’s awareness of abnormal movements (Guy 1976, 
Munetz 1988). The AIMS raters will be required to meet specific credential and educational 
criteria before they are certified to rate for this study. 
Further information regarding administration of the AIMS, including rater training and 
certification as well as recording AIMS scores will be provided in the Study Reference Manual. 
11.4.5.4. Barnes Akathisia Rating Scale (BARS) 
The BARS is a rating scale geared toward assessment of neuroleptic-induced akathisia, though it 
can be used to measure akathisia associated with other drugs as well. The BARS consists of 
four items, including one item assessing objective restlessness, two items targeting subjective 
restlessness (awareness and related distress), and one global clinical assessment item. All items 
are anchored and utilize a 4-point scale, except for the global rating which has a 6-point scale 
(from absence of akathisia through severe akathisia). The subjective and objective items are 
summed to yield a total score. The BARS can be administered in about 10 minutes (Barnes 1989, 
Barnes 2003, Schooler 2000). 
Further information regarding administration of the BARS, including rater training and 
certification as well as recording BARS scores will be provided in the Study Reference Manual. 
11.4.5.5. Modified Simpson-Angus Scale (SAS) 
The Modified SAS is a clinician-rated assessment of neuroleptic-induced Parkinsonism 
consisting of 10 items. Items are anchor-based, rated on a 5-point scale, and address rigidity, gait 
(bradykinesia), tremor, glabellar tap, and salivation (Simpson 1970). 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
52 
04 June 2018 
Further information regarding administration of the Modified SAS, including rater training and 
certification as well as recording scores will be provided in the Study Reference Manual. 
11.4.5.6. Physician Withdrawal Checklist 
Assessment of potential withdrawal effects will be conducted via the Clinician administered 
Physician Withdrawal Checklist (PWC) at the End of Treatment visit (Day 42 ± 2, after 
completion of efficacy and safety assessments and procedures scheduled for this visit are 
completed). The PWC will be administered again at the Follow-up visit (Day 49 ± 2). 
The PWC is used to evaluate symptoms of withdrawal after discontinuation of study medication. 
Symptoms are assessed as present or absent and if present then intensity is assessed as mild, 
moderate, or severe. 
11.5. 
Pharmacokinetic Assessments 
A validated enantioselective liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
method will be used for determination of plasma R- and S-amisulpride concentrations, and an 
enzyme-linked immunosorbent assay (ELISA) will be used for determination of plasma prolactin 
concentrations. 
Plasma concentrations of R-amisulpride, S-amisulpride, and prolactin will be assayed using 
plasma samples from blood collected according to the schedule of assessments (see Section 22, 
Appendix III for sample collection and handling guidelines). Blood collection date and times 
must be recorded. 
Remaining plasma samples after amisulpride PK and prolactin analysis may also be used for the 
additional characterization and/or bioanalytical method development of putative metabolites of 
amisulpride and for other exploratory measurements, if needed. 
Population PK analysis methods will be used to characterize the PK/PD profiles in subjects 
treated with SEP-4199. Results of population PK analysis will be described in a separate report 
other than the clinical study report. 
11.6. 
Study Visits and Assessments 
11.6.1. 
Screening: Visit 1 (Day -22 to -2) 
Subjects will be evaluated at the Screening Visit to determine their eligibility to enroll in the 
study. This visit should be scheduled as an early morning appointment due to subject 
requirement to fast for blood sample collection for clinical laboratory tests. Subjects should be 
advised to bring food items if not otherwise provided by the site. 
Per local clinical practice, subjects may be hospitalized for up to 7 days during the Screening 
period. Further need for hospitalization will require consultation with the Medical Monitor. 
To determine subject eligibility, abnormal Screening clinical laboratory tests may only be 
repeated after discussion with the Medical Monitor. 
To determine subject eligibility, Screening ECG may only be repeated due to technical issues. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
53 
04 June 2018 
The following study-related procedures will be performed at Visit 1; it is suggested that they be 
performed in the order presented below, as is possible by the site: 
• Obtain informed consent. 
• Perform SCID-5-CT. 
• Perform MADRS. To be eligible for enrollment, subjects must have a MADRS total 
score ≥ 22 (see Section 24, Appendix V). 
• Administer YMRS. To be eligible for enrollment, subjects must have a YMRS total 
score ≤ 12. 
• Administer C-SSRS (Screening/Baseline version). 
• Review inclusion and exclusion criteria. 
• Collect blood sample(s) for the following clinical laboratory tests: 
− Hematology and Serum Chemistry (If possible, subjects should fast for at least 
8 hours [no food after midnight] to avoid potential for retest.) 
− Serum Thyroid Stimulating Hormone 
− Serum Follicle Stimulating Hormone (Female Subjects) 
− Serum β-hCG (Female Subjects of childbearing potential) 
− Serum prolactin 
− Hemoglobin A1c (HbA1c) 
− Lipid Panel 
− Serum Insulin 
− high sensitivity (hs) C-reactive Protein 
• Collect blood sample for Hepatitis B/C testing. 
• Collect blood sample for R- and S-amisulpride PK and plasma prolactin analysis. 
• Collect urine sample for urine drug screen and urinalysis. 
• Record demographics. 
• Record medical history. 
• Record psychiatric history and mental status. Note: the psychiatric history includes a 
psychiatric history form that will include variables related to duration of illness, 
treatment response (eg, prior medications used to treat bipolar disorder) and other 
similar variables. 
• Record prior and concomitant medications. 
• Record pretreatment events. 
• Perform physical examination. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
54 
04 June 2018 
• Perform neurological examination. 
• Record height and weight. 
• Calculate and record BMI. 
• Obtain vital signs, including orthostatic changes in blood pressure and heart rate. 
• Perform 12-lead ECG. 
• Schedule next visit. 
11.6.2. 
Baseline and Treatment Period: Day -1 to Day 42 
11.6.2.1. Baseline: Visit 2 (Day -1) 
Per local clinical practice, subjects may be hospitalized for up to 7 days during the first week of 
treatment with double-blind study drug. Further need for hospitalization will require consultation 
with the Medical Monitor. 
The following study-related procedures will be performed at Visit 2; it is suggested that they be 
performed in the order presented below, as is possible by the site: 
• Review inclusion and exclusion criteria. 
• Collect blood sample(s) for the following clinical laboratory tests (Subjects must have 
fasted for at least 8 hours [no food after midnight].): 
− Hematology and Serum Chemistry 
− Serum prolactin 
− Hemoglobin A1c (HbA1c) 
− Lipid Panel 
− Serum Insulin 
− hs C-reactive Protein 
• Collect blood sample for R- and S-amisulpride PK and plasma prolactin analysis. 
• Collect urine sample for urine drug screen, urinalysis, and urine β-hCG (female 
subjects of childbearing potential). 
• Record prior and concomitant medications. 
• Record pretreatment events. 
• Administer MADRS: To be eligible for enrollment, subjects must have a MADRS 
total score ≥ 22. Subjects who have a decrease (improvement) of ≥ 25% in MADRS 
total score from Screening to Baseline, or who have a MADRS total score < 22 at 
Baseline will not be eligible for enrollment (see Section 24, Appendix V).  
• Administer HAM-A. 
• Administer YMRS. To be eligible for enrollment, subjects must have a YMRS total 
score ≤ 12. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
55 
04 June 2018 
• Administer SDS. 
• Administer QIDS-SR16. 
• Administer AIMS. 
• Administer BARS. 
• Administer Modified SAS. 
• Administer C-SSRS (Since Last Visit version). 
• Administer CGI-BP-S. 
• Administer EQ-5D-5L. 
• Perform physical examination. 
• Perform neurological examination. 
• Record weight. 
• Record waist circumference. 
• Obtain vital signs, including orthostatic changes in blood pressure and heart rate. 
• Perform 12-lead ECG. 
• Randomize subject. 
• Dispense study drug. 
• Instruct subject to administer a single oral dose of study medication approximately 
the same time each day at home beginning the following morning (Day 1). 
•  Schedule next visit: 
− Instruct subject to take the morning dose prior to the next clinic visit. Clinic visits 
are to begin no later than 6 hours postdose, if possible. 
− Instruct subject to record date and time of the last 3 doses prior to the next visit 
and to bring back all used/unused study drug and packaging to the next visit. 
11.6.2.2. Visit 3 (Day 7 ± 2) 
The following study-related procedures will be performed at Visit 3; it is suggested that they be 
performed in the order presented below, as is possible by the site: 
• Administer MADRS. 
• Administer HAM-A. 
• Administer YMRS. 
• Administer QIDS-SR16. 
• Administer AIMS. 
• Administer BARS. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
56 
04 June 2018 
• Administer Modified SAS. 
• Administer C-SSRS (Since Last Visit version). 
• Administer CGI-BP-S. 
• Record prior and concomitant medications. 
• Record adverse events. 
• Obtain vital signs, including orthostatic changes in blood pressure and heart rate. 
• Perform 12-lead ECG. 
• Ask subject the date and time of their last 3 doses of study drug and record in the 
source. 
• Collect used/unused study drug and packaging. 
• Perform study drug accountability. 
• Dispense study drug. 
• Instruct subject to dose once daily in the morning approximately the same time each 
day at home. 
• Schedule next visit: 
− Instruct subject to take the morning dose prior to the clinic visit. Clinic visits are 
to begin no later than 6 hours postdose, if possible. 
− Instruct subject to record date and time of the last 3 doses prior to next visit and to 
bring back all used/unused study drug and packaging to the next visit. 
11.6.2.3. Visit 4 (Day 14 ± 2) 
The following study-related procedures will be performed at Visit 4; it is suggested that they be 
performed in the order presented below, as is possible by the site: 
• Administer MADRS. 
• Administer HAM-A. 
• Administer YMRS. 
• Administer QIDS-SR16. 
• Administer AIMS. 
• Administer BARS. 
• Administer Modified SAS. 
• Administer C-SSRS (Since Last Visit version). 
• Administer CGI-BP-S. 
• Record prior and concomitant medications. 
• Record adverse events. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
57 
04 June 2018 
• Obtain vital signs, including orthostatic changes in blood pressure and heart rate. 
• Perform 12-lead ECG. 
• Collect blood sample(s) for the following clinical laboratory tests: 
− Hematology and Serum Chemistry 
− Serum prolactin 
• Collect blood sample for R- and S-amisulpride PK and plasma prolactin analysis. 
• Collect urine sample for urine drug screen, urinalysis, and urine β-hCG (female 
subjects of childbearing potential). 
• Ask subject the date and time of their last 3 doses of study drug and record in the 
source and the CRF. 
• Collect used/unused study drug and packaging. 
• Perform study drug accountability. 
• Dispense study drug. 
• Instruct subject to dose once daily in the morning at approximately the same time 
each day at home. 
• Schedule next visit: 
− Instruct subject to administer the morning dose prior to the clinic visit. Clinic 
visits are to begin no later than 6 hours postdose, if possible. 
− Instruct subject to record date and time of the last 3 doses prior to next visit and to 
bring back all used/unused study drug and packaging to next visit. 
11.6.2.4. Visit 5 (Day 28 ± 2) 
The following study-related procedures will be performed at Visit 5; it is suggested that they be 
performed in the order presented below, as is possible by the site: 
• Administer MADRS. 
• Administer HAM-A. 
• Administer YMRS. 
• Administer QIDS-SR16. 
• Administer AIMS. 
• Administer BARS. 
• Administer Modified SAS. 
• Administer C-SSRS (since last visit version). 
• Administer CGI-BP-S. 
• Record prior and concomitant medications. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
58 
04 June 2018 
• Record adverse events. 
• Obtain vital signs, including orthostatic changes in blood pressure and heart rate. 
• Perform 12-lead ECG. 
• Ask subject the date and time of their last 3 doses of study drug and record in the 
source. 
• Collect used/unused study drug and packaging. 
• Perform study drug accountability. 
• Dispense study drug. 
• Instruct subject to dose once daily in the morning at approximately the same time 
each day at home. 
• Schedule next visit: 
− Instruct subject to administer the morning dose prior to the clinic visit. Clinic 
visits are begin no later than 6 hours postdose, if possible. 
− Instruct subject to record date and time of the last 3 doses prior to next visit and to 
bring back all used/unused study drug and packaging to the next visit. 
11.6.2.5. Telephone Contact (Day 35 ± 2) 
The clinical site will contact subjects by telephone on Day 35 (± 2) to assess adverse events and 
concomitant medications. The clinical site will remind the subject of their next scheduled visit 
and to continue once daily dosing with study drug and to administer the morning dose prior to 
the next clinic visit. 
11.6.3. 
End of Treatment/Early Termination: Visit 6 (Day 42 ± 2) 
The following study-related procedures will be performed at Visit 6; it is suggested that they be 
performed in the order presented below, as is possible by the site: 
• Collect blood sample(s) for the following clinical laboratory tests (Subjects must have 
fasted for at least 8 hours [no food after midnight].): 
− Hematology and Serum Chemistry 
− Serum prolactin 
− Hemoglobin A1c (HbA1c) 
− Lipid Panel 
− Serum Insulin 
− hs C-reactive Protein 
• Collect blood sample for R- and S-amisulpride PK and plasma prolactin analysis. 
• Collect urine sample for urine drug screen, urinalysis, and urine β-hCG (female 
subjects of childbearing potential). 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
59 
04 June 2018 
• Administer MADRS. 
• Administer HAM-A. 
• Administer YMRS. 
• Administer SDS. 
• Administer QIDS-SR16. 
• Administer AIMS. 
• Administer BARS. 
• Administer Modified SAS. 
• Administer PWC. 
• Administer C-SSRS (Since Last Visit version). 
• Administer CGI-BP-S. 
• Administer EQ-5D-5L. 
• Perform physical examination. 
• Perform neurological examination. 
• Record weight. 
• Record waist circumference. 
• Record prior and concomitant medications. 
• Record adverse events. 
• Obtain vital signs, including orthostatic changes in blood pressure and heart rate. 
• Perform 12-lead ECG. 
• Ask subject the date and time of their last 3 doses of study drug and record in the 
source and CRF. 
• Collect used/unused study drug and packaging. 
• Perform study drug accountability 
• Schedule follow-up visit. 
11.6.4. 
Follow-up: Visit 7 (Day 49 ± 2) 
All subjects will have a follow-up visit 7 days after their last study drug dose. The following 
study-related procedures will be performed at Visit 7; it is suggested that they be performed in 
the order presented below, as is possible by the site: 
• Administer YMRS. 
• Administer PWC. 
• Administer C-SSRS (Since Last Visit version). 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
60 
04 June 2018 
• Record prior and concomitant medications. 
• Record adverse events. 
• Perform physical examination. 
• Record weight. 
• Record waist circumference. 
• Obtain vital signs, including orthostatic changes in blood pressure and heart rate. 
• Perform 12-lead ECG. 
• Collect blood sample(s) for the following clinical laboratory tests: 
− Hematology and Serum Chemistry 
− Serum prolactin 
• Collect blood sample for R- and S-amisulpride PK and plasma prolactin analysis. 
• Collect urine sample for urine drug screen, urinalysis, and urine β-hCG (female 
subjects of childbearing potential). 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
61 
04 June 2018 
12. 
SAFETY REPORTING 
12.1. 
Definitions 
12.1.1. 
Adverse Events 
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether 
or not considered drug related. 
Untoward medical occurrences that occur between the time of signing the informed consent form 
(ICF) and drug administration are pre-treatment events. Those that occur after administration of 
study drug are considered AEs. Pre-treatment hospitalizations that occur in accordance with local 
clinical practice during the screening period (for wash-out from prior or concomitant 
medications) will not be considered as SAEs and do not need to be reported as such. Any 
untoward event that may occur during the hospitalization must be recorded as a pretreatment 
event. If hospitalization is prolonged by an untoward event, the event must be reported as 
an SAE. 
An AE can, therefore, be any unfavorable and unintended sign (including an abnormal or 
clinically significant laboratory finding), symptom, or disease occurring after the administration 
of a medicinal (investigational) product, whether or not considered related to the medicinal 
(investigational) product. AEs may include the onset of new illness and the exacerbation of 
pre-existing conditions. 
The Investigator should attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical information. In such cases, the diagnosis should be documented as the AE 
and not the individual signs/symptoms. 
12.1.2. 
Serious Adverse Events 
A serious adverse event (SAE) is pretreatment event or an AE that meets one or more of the 
following criteria: 
• Results in death. 
• Is life-threatening. 
• Requires hospitalization or prolongation of existing hospitalization. 
• Results in persistent or significant disability or incapacity. 
• Is a congenital anomaly or birth defect. 
• Is an important medical event that may jeopardize the subject or may require a 
medical or surgical intervention to prevent one of the outcomes listed above. 
Examples of such medical events include allergic bronchospasm requiring intensive 
treatment in an emergency room or at home, blood dyscrasias or convulsions that do 
not result in inpatient hospitalization. 
The term “severe” is often used to describe the severity of a specific event (as in mild, moderate, 
or severe myocardial infarction) (see Section 12.3); the event itself, however, may be of 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
62 
04 June 2018 
relatively minor medical significance (such as severe headache). This is not the same as 
“serious,” which is based on subject/event outcome or action criteria usually associated with 
events that pose a threat to a subject's life or functioning as defined by the criteria above. 
During the study, if a subject has a hospitalization or procedure (eg, elective surgery) that was 
scheduled before the study entry, ie, before informed consent for an event/condition that 
occurred before the study, the hospitalization is considered a therapeutic intervention and not the 
result of a SAE. However, if the event/condition worsens during the study, it should be reported 
as an AE (or SAE, if the event/condition results in a serious outcome such as prolongation of 
hospitalization). 
Life-threatening means that the subject was, in the view of the Investigator, at immediate risk of 
death from the event as it occurred. This definition does not include an event that had it occurred 
in a more severe form might have caused death. 
SAE criteria information will be captured on the CRF. 
12.2. 
Objective Findings 
Clinically significant abnormal objective findings (eg, clinical laboratory value, ECG value, and 
physical examination observation) will also be recorded as AEs.  
When a clear diagnosis is available that explains the objective findings, this diagnosis will be 
recorded as the AE, and not the abnormal objective finding (eg, viral hepatitis will be recorded as 
the AE, not transaminase elevation). If a definite diagnosis is not available, then the sign 
(eg, clinically significant elevation of transaminase levels) or symptom (eg, abdominal pain) will 
be recorded as the AE. 
The Investigator listed on the Form FDA 1572 (MD or DO) (or Sub-Investigator MD or DO as 
described on the delegation log) will review ECG and laboratory reports and initial and date on 
all pages, or other acceptable documentation process approved by the Sponsor. Laboratory test 
and ECG results will be reviewed by the Investigator as they become available. The Investigator 
must determine the clinical significance of all out-of-range lab values (except drug screens) and 
abnormal ECG results. Possibly drug-related or clinically relevant abnormal values of uncertain 
causality must be repeated. Any abnormal values that persist should be followed at the discretion 
of the Investigator. Any value outside the normal range will be flagged for the attention of the 
Investigator or appropriate designee at the study center. The Investigator or appropriate designee 
will indicate whether or not the value is of clinical significance. If the result of any test (or repeat 
test, if done) from the samples taken during Screening is indicated as clinically significant and is 
not covered by the inclusion criteria in Section 8.1, the subject will not be allowed into the study. 
Additional testing during the study may be done if medically indicated. If a clinically significant 
abnormality is found in the samples taken after dosing, during the study, and/or at the Follow-Up 
Visit, this should be recorded as an AE and the subject will be followed until the test(s) has 
(have) normalized or stabilized. 
If a subject experiences symptoms or ECG findings suggestive of an arrhythmia during the 
study, the subject should be evaluated by a cardiac specialist. If such an arrhythmia is detected 
during the study and is thought to be immediately life-threatening (eg, torsades de pointes 
[TdP]), the subject is to be treated immediately following the site’s standard emergency 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
63 
04 June 2018 
procedures. An SAE will be reported, and the subject discontinued from the study drug. 
Emergency resuscitative equipment must be available at the site.  
In addition, subjects will be monitored throughout the study for clinical risk factors of TdP, such 
as electrolyte imbalances, bradycardia, sustained tachycardia and syncope. If a subject 
experiences such an adverse event, it will be managed immediately and followed until resolution. 
Subjects who, at any study visit post-baseline have a QTcF value greater than 500 ms or who 
have a > 60 ms increase in QTcF from baseline will be discontinued from the study drug and 
followed until the event resolves; in addition, an adverse event will be reported.  
Subjects who develop adverse events of amenorrhea, gynecomastia, or galactorrhea are to be 
discontinued from the study drug. 
12.3. 
Collection and Recording of Adverse Events 
All pre-treatment events and AEs must be recorded in the subject’s study records/source 
documents in accordance with the Investigator’s normal clinical practice. 
All pre-treatment events and AEs must be recorded on the CRF. 
Pre-treatment events will be recorded from the time informed consent is provided at screening 
until just prior to first study drug dose administration at Day 1. AEs will be recorded beginning 
after first study drug dose administration at Day 1 until the follow-up visit at Day 49. 
All AEs will be followed until resolution, stabilization of the condition, the event is otherwise 
explained, or the subject is lost to follow-up. 
Each AE is to be evaluated for duration, severity, frequency, seriousness, action taken with the 
study drug, outcome, and causal relationship to the study drug. Definitions for severity, 
frequency, action taken with the study drug, outcome, and causal relationship to the study drug 
are presented below. 
The severity of AE: 
• Mild - Ordinarily transient symptoms that do not influence performance of subject’s 
daily activities. Other treatment is not ordinarily indicated. 
• Moderate - Marked symptoms sufficient to make the subject uncomfortable. 
Moderate influence on performance of subject’s daily activities. Other treatment may 
be necessary. 
• Severe - Symptoms cause considerable discomfort. Substantial influence on subject’s 
daily activities. May be unable to continue the study, and other treatment may be 
necessary. 
The frequency of AE: 
• Once – an isolated episode. 
• Intermittent – occurs on two or more separate occasions. 
• Continuous – does not abate from date of onset to date of resolution. 
The action taken with the study drug: 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
64 
04 June 2018 
• Dose Not Changed 
• Drug Withdrawn – Study drug stopped permanently. 
• Not Applicable 
• Unknown 
The outcome of the AE: 
• Recovered/Resolved 
• Recovering/Resolving 
• Not Recovered/Not Resolved 
• Recovered/Resolved with Sequelae 
• Fatal 
• Unknown 
The causal relationship of the AE to the study drug: 
• Not related 
o Not related - Improbable temporal relationship and is plausibly related to 
other drugs or underlying disease. 
• Related 
o Possible - occurred in a reasonable time after study drug administration, but 
could be related to concurrent drugs or underlying disease. 
o Probable - occurred in a reasonable time after study drug administration, is 
unlikely to be attributable to concurrent drugs or underlying disease, and there 
is a plausible mechanism to implicate the study drug. 
o Definite - occurred in a reasonable time after study drug administration and 
cannot be explained by concurrent drugs or underlying disease. The AE 
should respond to dechallenge/rechallenge, however, this is not mandatory 
before assigning a definite causality. 
The Medical Advisor is the initial contact person for protocol related questions or discussion of 
AEs. The contact information for the Medical Advisor as well as other emergency contact 
information can be found in Table 1 of this protocol. 
12.4. 
Immediately Reportable Events 
The following medical events must be immediately reported to the Sponsor: 
• SAE 
• Pregnancy 
Emergency contact information can be found in Table 1. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
65 
04 June 2018 
12.4.1. 
Serious Adverse Event 
If the Investigator or study center staff becomes aware of an SAE that occurs in a study subject 
up to and including the final follow-up, this must be reported immediately to the Sponsor 
whether considered related or unrelated to the study drug. SAEs must be recorded on the CRF 
and the data recorded should agree with that on the SAE form. 
Following the end of subject participation in the study, the Investigator or an authorized delegate 
should report SAEs “spontaneously” to the Sponsor PPD Pharmacovigilance (PVG) if 
considered at least possibly related to the study drug. 
SAEs will be followed until resolution, loss to follow-up, stabilization of condition, or the event 
is otherwise explained. 
In addition to the initial telephone notification, an initial SAE form as applicable must be 
completed and signed and sent via fax or email (see Table 1) to the Sponsor PPD-PVG within 
24 hours of the Investigator or study center staff becoming aware of the event. The SAE form 
must be signed by the Investigator or appropriate designee. The Sponsor PPD-PVG provides the 
SAE form used to report SAEs. 
SAEs must be promptly reported to the Institutional Review Board (IRB) or Independent Ethics 
Committee (IEC) by the Principal Investigator or the appropriate person at the study center if 
required per IRB/IEC guidelines. 
The appropriate PVG group must be contacted immediately upon first knowledge of the incident. 
The immediate report should be made by the Investigator within a very short period of time and 
under no circumstances should this exceed 24 hours following knowledge of the SAE or 
pregnancy. 
Sunovion will review all SAE reports to determine if any SAEs are suspected unexpected serious 
adverse reactions (SUSARs). 
All fatal or life-threatening SUSARs must be reported as soon as possible, but no later than 
7 days after the sponsor first becomes aware of the reaction. Any additional relevant information 
must be sent within and additional 8 days of the clock date. All non-fatal or non-life-threatening 
SUSARs must be reported as soon as possible but no later than 15 days after the sponsor first 
becomes aware of the reaction. Sponsor safety reporting group will notify the applicable 
Regulatory Agencies of all SUSARs. 
12.4.2. 
Pregnancy 
Pregnancies that occur from the time that informed consent is signed through the final follow-up 
visit will be collected and reported on the Pregnancy Event Form. 
If a subject becomes pregnant during the course of the study, she will be instructed to return 
promptly/within 48 hours of the first notification of pregnancy to the study center and undergo a 
serum/urine pregnancy test, as confirmation of pregnancy. Every effort will be made to 
follow-up all pregnancies, including those in the female partner of male subjects, until resolution 
(ie, termination [voluntary or spontaneous] or birth), providing the volunteers consent to 
follow-up. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
66 
04 June 2018 
To report a pregnancy, the Pregnancy Event Form must be completed and sent via fax to 
PPD-PVG within 24 hours of the Investigator or study center staff becoming aware of the 
pregnancy. The Sponsor provides the Pregnancy Event Form. 
Pregnancy itself is not regarded as an AE unless there is a suspicion that the study drug may have 
interfered with the effectiveness of a contraceptive medication or other AEs were detected. 
12.5. 
Data and Safety Monitoring Board 
A Data and Safety Monitoring Board (DSMB) will review safety data at regular intervals. The 
DSMB will be independent of the Sponsor, CRO, and the Investigators and will be empowered 
to recommend stopping the study due to safety concerns, but not for efficacy or futility. The 
DSMB may review blinded, unblinded, or partially unblinded data, but the Sponsor (with the 
exception of the relevant members of the pharmacovigilance team responsible for reporting 
Suspected Unexpected Serious Adverse Reactions [SUSARs]), the CRO, and the Investigators 
will remain blinded until the official unblinding of the database. The membership of the DSMB 
and its mandate will be described in a separate DSMB charter. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
67 
04 June 2018 
13. 
TERMINATION OF SUBJECT FROM STUDY/ 
DISCONTINUATION OF STUDY DRUG 
13.1. 
Criteria for Subject Termination 
Subjects may terminate the study participation at any time for any reason. 
The possible reasons for the termination of study participation are as follows: 
• Adverse event. 
• Lack of efficacy (specify). 
• Lost to follow-up (specify). 
• Pregnancy. 
• Withdrawal by subject (specify). 
• Non-compliance with study drug (specify). 
• Protocol deviation (specify). 
• Death 
• Other (specify). 
If at any time during the course of the study, in the opinion of the Investigator, the subject may 
no longer safely participate due to a change in medical status (eg, experiences an AE, becomes 
pregnant), the subject must be discontinued from the study drug. 
Subjects who, at any study visit post-baseline have a QTcF value greater than 500 ms, who have 
a > 60 ms increase in QTcF from baseline, or who experience a life-threatening arrhythmia will 
be discontinued from the study drug and followed until the event resolves; in addition, an 
adverse event will be reported.  
Subjects who develop adverse events of amenorrhea, gynecomastia, or galactorrhea are to be 
discontinued from the study drug. The reason for discontinuation and information on the epoch 
will be recorded on the appropriate CRF. In case of death, the date of death should be captured 
on the CRF. 
Subjects who prematurely terminate the study participation will not be replaced. 
Subjects who discontinue prior to Visit 6 (Day 42 [± 2]) will undergo procedures and 
assessments scheduled for Visit 6 (Day 42 [± 2]) at the time of early discontinuation (see 
Section 11.6.3). 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
68 
04 June 2018 
14. 
STUDY TERMINATION 
The Sponsor reserves the right to discontinue the study at this study center or at multiple centers 
for safety or administrative reasons at any time while safeguarding that early termination does 
not compromise subjects’ safety or well-being. In particular, a study center that does not recruit 
at an acceptable rate may be closed. Should the study be terminated and/or the study center 
closed for whatever reason, all documentation and study medications pertaining to the study 
must be returned to the Sponsor or its representative. 
If, in the opinion of the Investigator, clinical observations suggest it may be unsafe to continue, 
the Investigator may terminate part or the entire study after consultation with the Sponsor. 
In the event of study or site termination, subjects will be required to return for a final study 
assessment 7 days after their last dose of study drug (ie, follow-up) and be provided with access 
to standard care. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
69 
04 June 2018 
15. 
STATISTICS 
The comprehensive statistical analysis plan (SAP) will provide details on the statistical methods 
planned for this study and will be finalized prior to the US and Europe cohort unblinding. 
15.1. 
Sample Size 
A total sample size of 279 evaluable subjects in US and Europe (93 per treatment group: 
SEP-4199 200 mg/day, SEP-4199 400 mg/day, and placebo) with a global 2-sided alpha of 0.05 
will provide about 90% power to reject at least 1 truly significant comparison and about 
75% power to reject both truly significant comparisons using the truncated Hochberg (γ = 0.9) 
procedure, assuming treatment effect sizes of 0.44 for both doses of SEP-4199. The effect sizes 
were selected considering the data from the completed lurasidone bipolar depression study 
(Loebel 2014). This effect size corresponds to a treatment difference of -3.85 for a SEP-4199 
dose with a common standard deviation of 8.745 on the MADRS scale change from baseline at 
Week 6. An upward adjustment of approximately 5% is used to compensate for information lost 
due to subjects who are randomized and do not provide any postbaseline primary efficacy data. 
The total sample size will be approximately 294 randomized subjects (or N = 98 subjects per 
treatment group). 
For the secondary efficacy endpoint, assuming the 93 subjects per treatment arm, the study will 
have 71% power to reject at least one truly significant comparison within the CGI-BP-S family 
using the regular Hochberg procedure, given a treatment difference of -0.47 for a SEP-4199 dose 
with a common standard deviation of 1.24 on the CGI-BP-S change from baseline at Week 6. 
The correlation between the primary and the secondary endpoint is assumed to be 0.8 for each 
treatment arm. 
The sample size was calculated using the Mediana package version 1.05 within R version 3.4.2 
(R Core Team 2017). 
The sample size for the Japanese cohort (45 total [N = 15 subjects per group], including 
9 dropouts) provides more than 80% probability to have a treatment difference point estimate 
greater than zero for the MADRS. 
15.2. 
Analysis Populations 
Each population below will be created for both the US and Europe cohort and the Japanese 
cohort. 
Intention-to-Treat Population: The intention-to-treat (ITT) population will consist of subjects 
who are randomized. Subjects are included in the ITT population regardless of any protocol 
deviations. Subjects will be analyzed according to their randomized treatment group. The ITT 
population is the primary population for all efficacy analyses. 
Per Protocol Population: These are all ITT subjects who have no important protocol deviations 
that may affect the interpretation of the primary efficacy endpoint as defined in Section 15.3.3. 
Subjects in the Per Protocol population will be analyzed according to their randomized 
treatment group. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
70 
04 June 2018 
Analysis of the primary and the secondary efficacy endpoints will also be performed using the 
Per Protocol population. 
Safety Population: The safety population will consist of all subjects who randomized and 
receive at least one dose of study medication. Subjects will be analyzed according to the 
predominant treatment received. The predominant treatment is defined as the treatment to which 
the subject is exposed for the greatest duration during the treatment period. This will generally be 
the same as the randomized treatment group, unless the subject takes incorrect study medication 
during their entire participation in the study. 
Pharmacokinetic (PK) Population: The PK population includes the Safety population subjects 
who have at least 1 valid postdose PK concentration value without protocol deviations or events 
with the potential to affect PK. The PK analysis will be based on the PK population. 
15.3. 
Data Analysis 
In general, all analyses of the Japanese cohort are descriptive in nature and will be reported 
separately from the US and Europe cohort, unless otherwise specified. 
Descriptive summaries will be provided where appropriate for each of the endpoints. In general, 
summaries will be presented by treatment arm within a population. 
In general, continuous outcomes will be summarized for the number of subjects, mean, 95% CI 
for the mean, standard deviation (SD), median, Q1, Q3, minimum and maximum. For categorical 
outcomes, the number and percentage of subjects will be presented. 
All statistical inference analyses will be performed with 2-sided tests at a significance level of 
0.05, unless otherwise specified. 
In general, for analyses of change from baseline, baseline will be defined as the last non-missing 
measurement collected up to and including the day of first dose of study medication. Baseline 
data will be presented for all subjects by treatment arm. 
All data from the CRFs, as well as any derived variables, will be presented in subject data 
listings. Unscheduled measurements will be included in the listings and will not be included in 
summary tables, unless specified otherwise. 
SAS® software Version 9.4 or higher will be used for all analyses. 
15.3.1. 
Subject Disposition 
The total number of screened subjects, the number of subjects who are screen failures, and the 
number of subjects randomized will be presented. The number and percentage of subjects who 
were randomly assigned to treatment and dosed and not dosed, who were included in each 
population will be summarized. The number and percentage of subjects who complete and 
discontinue study drug will be summarized, along with reasons for study drug discontinuation. 
Subject disposition will be displayed by each treatment arm and overall. 
15.3.2. 
Drug Exposure and Compliance 
Drug exposure and compliance will be summarized by treatment and overall for the Safety and 
ITT populations. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
71 
04 June 2018 
At each visit, prior to dispensing study medication, previously dispensed study medication will 
be retrieved and assessed by tablet count. The total number of doses between each treatment visit 
and overall for the entire study will be calculated for each subject. Compliance will be based on 
the number of doses expected to be taken. 
For subjects who discontinue study drug early, the last dose date will be the endpoint from which 
the scheduled number of doses will be calculated. For subjects who are lost to follow-up, and for 
whom the last dose date is unknown, the last contact date will be used. 
Compliance will be assessed by visit and overall, both continuously (mean percentage) and 
categorically (compliant vs. non-compliant, non-compliant < 75% and non-compliant > 125%, 
and subjects with any missing compliance). Treatment compliance will also be presented in a 
data listing. 
Exposure duration will be calculated using the number of days from the first dose through the 
last dose of study medication, inclusive. Exposure will be summarized both continuously overall 
and categorically (≥ 4 days, ≥ 7 days, ≥ 14 days, etc.) by planned visit days. 
15.3.3. 
Important Protocol Deviations 
Important protocol deviations (IPDs) will be identified and documented based on a review of 
potentially IPDs. The potentially IPDs will be identified through programmatic checks of study 
data, as well as through review of selected data listings. The potentially IPDs to be reviewed 
include, but are not limited to, subjects who: 
• Did not meet inclusion/exclusion criteria 
• Received any disallowed concomitant medication 
• Had compliance < 75% or > 125% 
• Other 
Additional IPDs may be identified from clinical review of Investigator comments or other data. 
Individual IPDs will be presented in a data listing. The number and percentage of subjects in the 
ITT population with IPDs will be summarized by type of deviation and randomized treatment 
group. 
15.3.4. 
Demographic and Baseline Characteristics 
Summaries for demographic characteristics and psychiatric history will be presented by 
treatment group and overall for the ITT, PP and Safety populations. Demographic characteristics 
include age (in years), age categories (< 55 years and ≥ 55 years), gender, race, ethnicity, 
country, geographic region (US, Europe and Japan), weight, height, body mass index, waist 
circumference as well as the MADRS total score, and the CGI-BP-S depression score at baseline. 
Summaries of other current psychiatric disorders present will include DSM-IV codes and 
Medical Dictionary for Regulatory Activities (MedDRA®), Version 20.1 or higher, preferred 
terms and will be provided for the ITT, PP and Safety populations. 
The medical history of each subject will be coded by system organ class (SOC) and preferred 
term (PT) using the MedDRA, Version 20.1 or higher. The number and percentage of subjects 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
72 
04 June 2018 
with medical history findings in each SOC and PT will be summarized by treatment group and 
overall for the Safety and ITT populations. 
15.3.5. 
Efficacy Analyses 
In general, all efficacy analyses of the Japanese cohort are descriptive in nature, any additional 
analysis details will be provided in the SAP. 
15.3.5.1. Primary Efficacy Endpoint Analysis 
The primary efficacy endpoint is the change from baseline in the MADRS total score at Week 6. 
The primary efficacy estimand is defined as the efficacy of each SEP-4199 dose over placebo for 
6 weeks, calculated as the difference in the primary efficacy endpoint between each SEP-4199 
treatment group and the placebo treatment group in the ITT population. This estimand, which 
will only include those subjects who participate in sites located in US and Europe, provides an 
estimate of the efficacy of each SEP-4199 dose over placebo, should a subject be able to tolerate 
and adhere to treatment for 6 weeks. 
The efficacy of SEP-4199 in terms of the MADRS total score will be evaluated using the 
following two null hypotheses: 
H1: There is no difference in mean change from baseline at Week 6 on the MADRS total 
score in the SEP-4199 200 mg treatment arm compared to Placebo. 
H2: There is no difference in mean change from baseline at Week 6 on the MADRS total 
score in the SEP-4199 400 mg treatment arm compared to Placebo. 
The alternative hypothesis for each of the null hypotheses is that there is a difference, 
respectively. If at least, one of the primary comparisons demonstrate a significant result, the 
study will be considered positive. 
The primary efficacy endpoint will be analyzed for the ITT population by means of an MMRM 
analysis, with change from baseline in the MADRS total score as the response variable and with 
factors for treatment group, visit, region, baseline MADRS total score, and the treatment-by-visit 
interaction. This analysis method makes a missing at random (MAR) assumption to the missing 
primary efficacy endpoints. The Kenward Roger approximation will be used to estimate 
denominator degrees of freedom. An unstructured covariance matrix will be used for the 
within-subject correlation. A robust sandwich estimator for the standard error of the fixed effects 
(Diggle 2002) along with a spatial exponential or a spatial power covariance structures will be 
assumed sequentially in case of a convergence problem. The first covariance structure to yield 
convergence will be used in the analysis. 
The Least Square (LS) mean treatment differences (each SEP-4199 group minus placebo) of 
change from baseline at Week 6, their 2-sided 95% CIs, and the associated p-values will be 
calculated based on the MMRM. 
Multiplicity adjustment to control the global familywise Type I error rate at 5% is described in 
Section 15.3.5.4. 
The normality assumption underlying the primary MMRM model will be assessed graphically. 
Details will be provided in the SAP. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
73 
04 June 2018 
An additional exploratory analysis with the Japanese cohort primary efficacy data will be 
performed by replacing region (US, EU) with region (US, EU, and Japan) in the primary 
MMRM model. The Japanese cohort alone will also be analyzed using an MMRM method. 
Details will be provided in the SAP. 
15.3.5.1.1. Sensitivity Analyses 
To address early dropouts under the assumption of missing not at random (MNAR), a 
pattern-mixture model (PMM) using a placebo-based multiple imputation method and a pattern 
mixture model using multiple imputations with penalties (ie, tipping point analysis by deflating 
the individually estimated treatment effect size by known factors) will be performed as 
sensitivity analyses to explore the robustness of the MMRM results for the primary analysis 
based on the ITT population. 
MADRS total score change from baseline values over time for dropouts and for completers will 
be plotted by visit dropout and reason for discontinuation categorizations to assess the impact of 
dropouts on the efficacy endpoints. Subjects will be grouped by the visit at which they had their 
last efficacy score measured. This will result in five categories of subject discontinuation: 
Week 1 dropouts, Week 2 dropouts, Week 4 dropouts, Week 6 dropouts and Completers. 
15.3.5.1.2. Supportive Analyses 
The primary efficacy endpoint will be analyzed using an analysis of covariance (ANCOVA) on 
the ITT population as supportive analysis. The model will include terms for treatment, region 
and baseline MADRS total score as covariate. The LS mean of treatment differences (each 
SEP-4199 group minus placebo), their 2-sided 95% CIs, and the associated p-values will be 
obtained from the model. 
The primary MMRM analysis will be repeated for the PP population to examine the impact of 
protocol deviations. 
A supplementary analysis of the primary efficacy of SEP-4199 will be conducted to explore the 
dose response relationship using the Multiple Comparison Procedure – Modelling (MCP-Mod) 
methodology. Possible dose response shapes to assess include linear, quadratic, Emax, and 
sigmoidal Emax. The best model fit will be selected using the minimum Akaike information 
criterion out of the statistically significant multiple contrast tests based on optimal contrast 
coefficients. Once the best model is selected, target dose(s) of interest including the minimum 
effective dose will be explored. 
Details will be provided in the SAP for any additional supportive analyses. 
15.3.5.2. Secondary Efficacy Endpoint Analyses 
The secondary efficacy endpoint, the CGI-BP-S score, will be analyzed by the MMRM method 
described for the primary efficacy endpoint using the ITT population with the appropriate 
baseline used as the covariate. 
The secondary endpoint will be tested once at least one primary endpoint is deemed significant 
using a mixture-based gate-keeping approach to control the global familywise Type I error rate. 
The details are described in Section 15.3.5.4. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
74 
04 June 2018 
The MMRM analysis will be repeated using the PP population for the secondary endpoints. Both 
endpoints will also be analyzed using an ANCOVA model with treatment, region as fixed effects 
and appropriate baseline as a covariate for the ITT population. 
Sensitivity analyses similar to the primary endpoint will be repeated for the secondary efficacy 
endpoint. Details will be provided in the SAP. 
Details will be provided in the SAP for the secondary efficacy endpoint analyses and any 
additional supportive analyses. 
15.3.5.3. Other Efficacy Endpoint Analyses 
All other efficacy endpoints will be performed using the ITT population. 
The HAM-A and the QIDS-SR16 total scores will be analyzed by the MMRM method described 
for the primary efficacy endpoint with the appropriate baseline as the covariate. 
The HAM-A, the QIDS-SR16, the SDS, and the EQ-5D-5L total scores will be analyzed using 
an ANCOVA model with treatment, region as fixed effects, and appropriate baseline as a 
covariate. 
A MADRS total score responder is defined as achieving a ≥ 50% reduction from the baseline 
total score. The MADRS total score responder proportions at Week 6 will be compared among 
the 3 treatment arms using logistic regression. This model will include treatment and region as 
fixed effects and baseline MADRS score as a covariate. 
The log rank testing method will be used to test for differences among the treatments for time to 
MADRS responder response. Subjects discontinuing the study and those completing the study 
without meeting the criteria for MADRS response will be censored at the date of treatment 
discontinuation or, if unknown, the date of last contact. The analysis will be supplemented with 
Kaplan-Meier curves to illustrate the differences among the three treatments. 
A cumulative distribution curve for all treatment groups will be presented, plotting the 
cumulative percent of MADRS responders versus the change from baseline in MADRS total 
score at Week 6. 
Remission incidence rates will be analyzed similarly to the MADRS responder analysis. 
Details will be provided in the SAP for the other efficacy endpoint analyses and any additional 
supportive analyses. 
15.3.5.4. Adjustment for Multiplicity 
A mixture-based gatekeeping approach using the truncated Hochberg (γ = 0.9) will be used to 
control the global FWER at 5% for the primary (E1) and secondary endpoint (E2) 
(Dmitrenko 2017). Using this method, a hypothesis is testable in a latter family only if the 
hypothesis in the former family associated with the same dose level is rejected. 
The hypotheses associated with the primary and the secondary endpoint will be grouped into 
2 hierarchical families as seen in Figure 2. 
• Family F1: SEP-4199 200 mg/day versus placebo (H1), and SEP-4199 400 mg/day 
versus placebo (H2), based on change from baseline in MADRS total score at 
Week 6 (E1) 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
75 
04 June 2018 
• Family F2: SEP-4199 200 mg/day versus placebo (H3), and SEP-4199 400 mg/day 
versus placebo (H4) based on change from baseline in CGI-BP-S depression score at 
Week 6 (E2) 
Figure 2: 
Hierarchy of Testing for Primary and Secondary Endpoints 
 
 
The mixture-based gatekeeping procedure will be performed in 2 steps: 
• Step 1: The SEP-4199 vs placebo comparisons for E1 (hypotheses H1 and H2) will be 
performed using a truncated Hochberg (γ = 0.9) test. 
• Step 2: The SEP-4199 vs placebo comparisons for E2 (hypotheses H3 and H4) will be 
performed using a regular Hochberg test only when the corresponding comparisons 
from Step 1 are rejected. For example, H4 is tested only if H2 is rejected. 
The primary efficacy analysis will be repeated for the PP population to provide additional 
information on the robustness of the primary efficacy results. The Hochberg procedure will not 
be used for the PP population. 
15.3.5.5. Efficacy Subgroup Analyses 
Subgroups, including but not limited to country, gender (male, female), race (White and Non-
white for the statistical model, the rest of categories, Black/African American, Asian, American 
Indian/Alaskan Native, Native Hawaiian/Pacific Islander, Other, will also be summarized), 
ethnicity (Hispanic and non-Hispanic), age groups, and bipolar I diagnosis subtype (rapid cycling 
and non-rapid cycling) will be detailed in the SAP. For the primary and the secondary efficacy 
endpoints, analysis will be performed for the subgroups with the same MMRM with additional 
terms for the subgroup, subgroup-by-treatment interaction, subgroup by visit interaction and 
subgroup-by-treatment-by visit interaction using the ITT population. For the country analyses, 
region will be replaced with country. Summary statistics and the LS mean treatment differences 
(each SEP-4199 group minus placebo) of change from baseline at Week 6, their 2-sided 
95% CIs, and the associated p-values will be provided as well as the p-value for the treatment-
by-subgroup interaction. 
15.3.6. 
Safety Analyses 
In general, safety analysis will be repeated for the Japanese cohort using descriptive statistics. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
76 
04 June 2018 
15.3.6.1. Adverse Events 
All AEs will be coded using Medical Dictionary for Regulatory Activities (MedDRA) 
version 20.1 or higher. AEs are untoward medical occurrences: 
• that occurred on or after the first dose of study medication, 
• with a missing start date and a stop date on or after the first dose of study medication, 
or 
• with both a missing start and stop date. 
The following AEs will be summarized and presented by treatment group and by MedDRA SOC 
and PT for the Safety population: 
• All AEs (including number of events and subject incidence). 
• AEs by severity (mild, moderate, severe). 
• AEs by relationship to the study drug (related, or not related). 
The following conventions will be followed in summarizing AEs: 
• For subject incidence summaries, each subject will be counted only once within each 
SOC and within each preferred term. 
• If a subject reports more than one AE within a preferred term and/or a body system, 
the AE with the highest known severity within each body system and within each 
preferred term will be included in the summaries by severity. 
• For summaries by relationship to the study medication, AEs will be grouped as 
“related” or “not related.” AEs assessed as “possible,” “probable,” or “definite,” will 
be grouped as “related.” If a subject reports more than one AE within the same 
treatment regimen, SOC and PT, and any are related, it will be summarized as related. 
Summaries of SAEs, non-serious AEs with a 5% cutoff, and AEs leading to study drug 
discontinuation will be provided. Additional summaries may be provided using AEs of special 
interest. 
A listing of all AEs will be provided, as well as a listing of deaths, a listing of SAEs, a listing of 
AEs leading to study drug discontinuation and a listing of pre-treatment untoward 
medical events. 
15.3.6.2. Treatment-Emergent Mania 
Number and percentage of patients with treatment-emergent mania, as assessed by the YMRS 
total score of ≥ 16 on any 2 consecutive visits or at the final assessment, or an AE of mania or 
hypomania will be summarized by treatment group. Mania incidence rates will be analyzed 
similarly to the MADRS responder analysis. The mania indicator will be set to 1 if the subject 
exhibits post-baseline mania, and 0 if the subject does not experience post-baseline mania and 
has at least 1 non-missing post-baseline YMRS total score, and missing otherwise. 
The change from baseline in the YMRS total score will also be analyzed using the MMRM 
method described above for the primary efficacy variable and appropriate baseline as a covariate. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
77 
04 June 2018 
15.3.6.3. Clinical Laboratory Assessments 
All summaries involving clinical chemistry, hematology, and urinalysis tests will be based on the 
Safety population. 
Descriptive statistics for absolute value and change from baseline will be displayed at each visit 
by treatment group for each chemistry, hematology, and urinalysis laboratory test measured on a 
continuous scale. Serum prolactin values will be summarized by treatment group and gender. 
Nonparametric rank ANCOVA with adjustments for baseline value will be applied to change 
from baseline in serum prolactin, lipids, glucose, for comparison between each SEP-4199 group 
and placebo. Serum prolactin will be assessed separately by gender. 
The normal reference ranges for laboratory tests will be used to determine whether the laboratory 
test value is below, within, or above the normal range. Shifts from baseline will be produced by 
treatment group to show the percentage of subjects with laboratory test values below, within, and 
above the normal range. 
The number and percentage of subjects with a Markedly Abnormal Post-baseline Laboratory 
value (MAPLV, to be defined in the SAP) for select parameters will be summarized by 
post-baseline visit and overall for each treatment group. 
The data listings for laboratory parameters will flag values outside of the reference range. 
15.3.6.4. ECGs 
All ECG summaries will be based on the Safety population. ECG parameters will include 
ventricular heart rate, PR interval (msec), RR interval (msec), QRS duration, QT interval, and 
corrected QT intervals (Bazett’s QTcB and Fridericia’s QTcF). 
Summary statistics for the actual values and change from baseline will be presented by treatment 
group at each time point for each parameter. 
Shifts from baseline will be produced by treatment group to show the number and percentage of 
subjects for changes in overall ECG assessments at post-baseline. 
The number and percentage of subjects with elevated QTc intervals (> 450 msec for males, 
> 470 msec for females, > 480 msec and > 500 msec for males or females) and changes from 
baseline in QTc intervals ≥ 30 msec, but < 60 msec and ≥ 60 msec will be summarized by 
treatment group. A listing displaying ECG values for subjects with at least one prolonged QTc 
will also be produced. 
For other ECG parameters, subjects will be classified as normal or abnormal (see SAP for 
details). For abnormal ECG parameter reporting, counts and percentages of subjects will be 
presented by treatment group. 
For these categorical analyses, the percent of subjects will be based on the number of subjects 
with at least one non-missing post treatment value. Any early termination visit or unscheduled 
ECG that occurs after first dose will be included for these posttreatment summaries. 
Electrocardiogram clinical interpretation of ECG findings will be presented in data listings. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
78 
04 June 2018 
15.3.6.5. Vital Signs 
All vital sign summaries will be based on the Safety population. 
Summary statistics for actual values and the change from baseline will be presented by treatment 
group, for each time point and each parameter. 
Nonparametric rank ANCOVA with adjustments for baseline value will be applied to change 
from baseline in weight and BMI for comparison between each SEP-4199 group and placebo. 
The number and percentage of subjects with Markedly Abnormal Post-baseline Vital Signs 
(MAPVS, defined in the SAP) will be presented at each post-baseline visit and overall. Included 
will be subjects having experienced MAPVS at least once post-baseline. 
The number and percentage of subjects with orthostatic hypotension and orthostatic tachycardia 
will be summarized by treatment by time point and overall. Orthostatic hypotension is defined as 
a decrease of ≥ 20 mmHg in systolic blood pressure or ≥ 10 mmHg in diastolic blood pressure 
after the subject had been standing for at least 2 to 4 minutes, compared to the systolic and 
diastolic blood pressures measured in the supine position, respectively. Orthostatic tachycardia is 
defined as a heart rate increase of at least 20 beats per minute (bpm) and a heart rate > 100 bpm 
after the subject was standing for at least 2 to 4 minutes, compared to the heart rate measured in 
the supine position. 
15.3.6.6. Movement Disorder Measures 
Descriptive statistics for absolute value and change from baseline will be displayed at each visit 
by treatment group for the AIMS, BARS and Modified SAS total scores. 
Each total score will be analyzed using MMRM and ANCOVA based on the change from 
baseline to Week 6 similar to the primary efficacy endpoint, with the respective baseline values 
as covariate. 
Any additional analysis details will be provided in the SAP. 
15.3.6.7. Columbia-Suicide Severity Rating Scale (C-SSRS) 
Frequency and severity of suicidal ideation or suicidal behavior in the C-SSRS will be 
summarized at each visit and overall by treatment group. Responses to each of the questions will 
be listed. 
15.3.6.8. Neurological and Physical Examination 
Findings from the physical and neurological examinations will be presented as follows: 
pre-existing clinically significant conditions recorded as medical history will be summarized, and 
new clinically significant conditions recorded as an AE. 
15.3.6.9. Concomitant Medications 
All medications will be coded to indication-specific ATC (Anatomical Therapeutic Chemical) 
classification (ie, ATC level 3) and PT according to the World Health Organization drug 
dictionary (WHO-DD) ATC classification level 3 and Preferred Term (PT) (1 Sept 2017 or more 
recent). 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
79 
04 June 2018 
Any medications taken during the course of the study, with a start date on or after the date of the 
first dose of study drug and on or before the date of the last dose of study drug; or with a start 
date prior to, and an end date on or after, the date of the first dose of study drug, or marked as 
ongoing, will be considered concomitant medications. Medications that ended prior to the date of 
the first dose of study drug will be considered prior medications. Medications that started after 
the date of the last dose of study drug will not be considered concomitant, but will be considered 
post-treatment. 
A detailed listing of prior, concomitant, and post medications taken by subjects will be provided. 
The number and percentage of subjects using concomitant medication will be summarized by 
treatment group by ATC and PT using the Safety population. Subjects with multiple uses of a 
medication will be counted only once for a given drug class or PT. 
15.3.6.10. Safety Subgroup Analyses 
Select safety data may be presented by geographic region, age, gender, and/or race subgroups. 
Details will be provided in SAP. 
15.3.7. 
Pharmacokinetic Analysis 
All PK analysis will be performed using the PK population. 
The PK collection times and deviations and/or any values excluded from analysis will be 
presented in data listings. Any plasma concentration summary statistics below the limit of 
quantification will be represented by “BLQ” in tables and listings. 
Concentrations at each scheduled sample collection time point will be summarized descriptively 
(n, mean, median, minimum, maximum, coefficient of variation [CV] and if appropriate, 
geometric mean and geometric CV [GCV]). All PK summaries will be presented by dose. 
The complete methodology and results of the population pharmacokinetic/pharmacodynamic 
analyses will be reported separately from the SAP as an appendix to the CSR. 
The relationship between SEP-4199 PK and plasma prolactin will also be explored as an 
appendix to the CSR. 
15.3.8. 
Interim Analysis 
There is no planned interim analysis for the primary analysis of the US and EU subjects. 
Following completion of the US and Europe cohort, a US and Europe only unblinding will be 
performed to analyze all related data. The primary analysis will be based on US and EU subjects. 
All Type I error will be used during this analysis. 
Additional analyses will be performed after completion of the Japanese cohort. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
80 
04 June 2018 
15.3.9. 
Treatment of Missing Data 
If one or more items of the MADRS total score are missing at a visit, the total score will be set 
to missing. For other scales with missing items, the total or subtotal score will be defined in 
the SAP. 
For the MMRM models, no imputation for missing data will be applied. 
Details of incomplete/missing dates for any endpoint will be provided in the SAP. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
81 
04 June 2018 
16. 
PROCEDURE FOR CLINICAL STUDY QUALITY 
CONTROL/DATA COLLECTION, MANAGEMENT, AND 
QUALITY ASSURANCE 
16.1. 
Data Collection/Electronic Data Capture (EDC) 
The results from Screening and data collected during the study (except clinical laboratory test 
results) will be recorded in the subject’s electronic CRF. The study centers will use an EDC 
system that is compliant with relevant FDA regulatory requirements per 21 CFR Part 11 
(Medidata Rave). Password protected access to the EDC system will be via a secure website. 
Data queries and data corrections will be handled through the same system. All transactions 
within the EDC system are fully documented within an electronic audit trail. Each set of 
completed CRFs must be reviewed and electronically signed and dated by the Investigator. 
16.2. 
Computerized Systems Used for Source Data 
A list of the computerized systems that will be used to create, modify, maintain, archive, retrieve, 
or transmit source data are presented below, pursuant to the Guidance for Industry Computerized 
Systems Used in Clinical Investigations, May 2007. 
Table 6: 
Computerized Systems Used for Source Data 
Protocol Step  
Computerized System Type or 
Description 
Informed consent 
A 
Inclusion/Exclusion Criteria Review 
A 
Randomization 
B 
Dispense Study Drug 
B 
Administer Study Drug 
A/B 
Study Drug Accountability 
B 
Prior/Concomitant Medications 
A 
Pretreatment Event Monitoring 
A 
Adverse Event Monitoring 
A 
Medical History 
A 
Psychiatric History/Mental Status 
A/C 
Structured Clinical Interview for DSM-5-Clinical Trial Version (SCID-5-CT) 
C 
Physical Examination 
A 
Height 
A 
Weight (Including Body Mass Index) 
A 
Waist Circumference 
A 
Vital Signs 
A 
12-Lead Electrocardiogram (ECG) 
A 
Montgomery-Asberg Depression Rating Scale (MADRS) 
C 
Hamilton Rating Scale for Anxiety (HAM-A) 
C 
Columbia-Suicide Severity Rating Scale (C-SSRS) 
C 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
82 
04 June 2018 
Table 6: 
Computerized Systems Used for Source Data (Continued) 
Protocol Step  
Computerized System Type or 
Description 
Young Mania Rating Scale (YMRS) 
C 
Sheehan Disability Scale (SDS) 
C 
Quick Inventory of Depressive Symptomatology – Self-Report  
(QIDS-SR16) 
C 
Abnormal Involuntary Movement Scale (AIMS) 
C 
Barnes Akathisia Rating Scale (BARS) 
C 
Modified Simpson-Angus Scale (SAS) 
C 
Clinical Global Impression – Bipolar Version-Severity of Illness 
(CGI-BP-S) 
C 
Physician Withdrawal Checklist 
C 
EuroQoL 5 dimensional questionnaire (EuroQoL-5D-5L) 
C 
Hepatitis B/C 
A 
Urine Drug Screen 
A 
Serum Thyroid Stimulating Hormone 
A 
Serum Follicle Stimulating Hormone (Female Subjects) 
A 
Serum β-hCG (Female Subjects of child-bearing potential) 
A 
Urine β-hCG (Female Subjects of child-bearing potential) 
A 
Hematology, Serum Chemistry, and Urinalysis 
A 
Serum Prolactin 
A 
Hemoglobin A1c (HbA1c) 
A 
Lipid Panel 
A 
Serum Insulin and C-reactive Protein 
A 
R- and S-Amisulpride Pharmacokinetic and Plasma Prolactin Blood Sample 
A 
Statistical analysis 
SAS® software, version 9.4 or higher 
Abbreviations: EDC = electronic data capture; eCOA = electronic clinical outcome assessments; IXRS = interactive 
response system; PK = pharmacokinetic(s). 
A = EDC; B = IXRS; C = eCOA. 
16.3. 
Study Monitoring 
This study will be monitored from initiation to completion by the Sponsor or its representative. 
Monitoring will include personal visits and telephone communication to assure that the 
investigation is conducted according to protocol and in order to comply with ICH GCP. On-site 
review of CRFs will include a review of forms for completeness and clarity, and consistency 
with source documents available for each subject. 
16.4. 
Audits 
The study may be subject to audit by the Sponsor/designee. If such an audit occurs, the 
Investigator must agree to allow access to required subject records. This is dependent on the 
subject granting consent by signing the ICF. By signing this protocol, the Investigator grants 
permission to personnel from the Sponsor or its representatives for on-site monitoring and 
auditing of all appropriate study documentation, as well as on-site review of the procedures 
employed in CRF generation, where clinically appropriate. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
83 
04 June 2018 
In accordance with ICH GCP the Sponsor may select this study for audit. During the audit the 
Sponsor representative will carry out an inspection of center facilities (eg, pharmacy, drug 
storage areas, laboratory) and review study related records in order to evaluate the study 
compliance with the Sponsor/center SOPs, protocol, ICH GCP and local regulations. The PI or 
appropriate designee must also agree to inspection of all study documents by the regulatory 
authorities and the IEC. Should the PI or appropriate designee be notified of a regulatory 
inspection involving this study they should notify the Sponsor immediately. 
16.5. 
Study Documentation 
Study records are comprised of source documents, CRFs, and all other administrative 
documents, eg, IRB/IEC correspondence, clinical study materials and supplies shipment 
manifests, monitoring logs, Sponsor and CRO correspondence, etc. A study specific binder will 
be provided with instructions for the maintenance of study records. 
Source document is defined as any hand written or computer generated document that contains 
medical information or test results that have been collected for or are in support of the protocol 
specifications, eg, clinical laboratory reports, clinic notes, drug disbursement log, subject sign in 
sheets, subject completed questionnaires if applicable, telephone logs, ECGs, etc. All draft, 
preliminary and pre-final iterations of a final report are also considered to be source documents, 
eg, faxed laboratory reports and hard copy laboratory reports, faxed initial results and hard copy, 
final report. 
16.6. 
Clinical Laboratory Certification and Normal Values 
A central laboratory will be used for analysis for most of the clinical laboratory tests for this 
study. The central laboratory will provide the Investigator, Sponsor/CRO with laboratory 
certification(s), a dated copy of normal range values for the central clinical laboratory selected to 
analyze clinical specimens. If an exception is granted to use a local laboratory, the Investigator 
must supply the Sponsor/CRO with laboratory certification, lab director’s curricula vitae and a 
current, dated copy of normal range values. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
84 
04 June 2018 
17. 
ETHICAL AND REGULATORY OBLIGATIONS 
17.1. 
Study Conduct 
The Investigator agrees that the study will be conducted according to the protocol, ICH Good 
Clinical Practice (GCP), ICH guidelines and the ethical principles that have their origin in the 
Declaration of Helsinki. The Investigator will conduct all aspects of the study in accordance with 
applicable local law(s) and regulation(s). 
The Investigator will assure proper implementation and conduct of the study including those 
study-related duties delegated to other appropriately qualified individuals. The Investigator will 
assure that study staff cooperate with monitoring and audits. 
The Investigator must sign and return to Sponsor/CRO the “Investigator Approval” page. 
The Investigator must provide a copy of current curriculum vitae (including a copy of a current 
medical license, current Drug Enforcement Agency (DEA) license, where applicable), and 
financial disclosure information. In countries where medical licensure is not issued, the 
following documentation is acceptable, as applicable: 
• Registration number/stamp with a registration number stated on curriculum vitae. 
• Appropriate diploma number stated on curriculum vitae. 
• Copy of the diploma. 
The Investigator must sign and return a completed Form FDA 1572 Statement of Investigator to 
Sponsor/CRO. 
17.2. 
Institutional Review Board/Independent Ethics Committee 
Documented approval for conducting the study from appropriate Institutional Review Board 
(IRB)/Independent Ethics Committee (IEC) will be obtained for all participating study centers 
prior to initiation of the study, according to ICH GCP, applicable local law(s) and regulation(s). 
When necessary, an extension, amendment or renewal of the IRB/IEC approval must be obtained 
and also forwarded to the Sponsor. The IRB/IEC must supply the Sponsor a list of the IRB/IEC 
membership, and a statement to confirm that the IRB/IEC is organized and operates according to 
ICH GCP, applicable law(s) and regulation(s). 
A copy of written IRB/IEC approval or favorable opinion of the protocol, informed consent form 
and subject recruitment material (if applicable) must be provided to Sponsor/CRO prior to start 
of the study. The approval or favorable opinion letter must be signed by the IRB/IEC chairman 
or designee identify the IRB/IEC name and address, identify the clinical protocol by title and/or 
protocol number, and include the date that approval or favorable opinion was granted. The letter 
must also contain a statement that the IRB/IEC complies with the requirements in 
21 CFR Part 56 for a study conducted under a US IND or ICH GCP, as applicable. 
The Investigator/CRO is responsible for obtaining from the IRB/IEC continued review of the 
clinical research or submitting periodic progress reports, in accordance with applicable 
regulations, at intervals not to exceed one year and (if applicable) as otherwise additionally 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
85 
04 June 2018 
specified by the IRB/IEC. The Sponsor must be supplied with written documentation of 
continued review of the clinical research. 
The Investigator must promptly inform their IRB/IEC of all SAEs reported by subjects enrolled 
in the study or other safety information reported from Sponsor/CRO in accordance with 
applicable law(s) and regulation(s). 
17.3. 
Informed Consent 
The Investigator will prepare the informed consent form and provide the form to Sponsor/CRO 
for approval prior to submission to the IRB/IEC. 
The informed consent form will be approved by the Sponsor/CRO prior to submission to the 
IRB/IEC. The Sponsor/CRO may provide a template informed consent form to be qualified by 
each research facility to conform to local requirements. All informed consent forms must contain 
the minimum elements as mandated by ICH GCP, applicable local law(s) and regulations and 
will be subject to Sponsor/CRO approval as well as IRB/IEC approval. The Sponsor/CRO may 
submit informed consent forms to a central IRB/IEC for review and approval or favorable 
opinion contingent upon prior Investigator permission and review. 
Before recruitment and enrollment, each prospective subject will be given a full explanation of 
the study, allowed to read the approved informed consent form and be provided ample time and 
the opportunity to ask any questions that may arise. Once all questions have been answered and 
the Investigator is assured that the prospective subject understands the implications of 
participating in the study, the prospective subject will be asked to give consent to participate in 
the study by signing the informed consent form. As part of the consent process, each prospective 
subject must consent to direct access to his/her medical records for study-related monitoring, 
auditing, IRB/IEC review, and regulatory inspection. It should be clearly explained to each 
prospective subject that participation in each and every clinical visit and assessment is expected. 
The subject may be discontinued from study medication, but that does not necessarily negate the 
expectation that the subject will continue to participate in the study through the final 
visit/assessment. The Investigator will provide a copy of the signed informed consent form to 
each subject, and will record the date of the informed consent on the CRF. 
If an amendment to the protocol changes the subject participation schedule in scope or activity, 
or if important new information becomes available that may be relevant to the subject’s consent, 
the informed consent form must be revised, submitted to the IRB/IEC for review and approval or 
favorable opinion. The revised informed consent form must be used to obtain consent from a 
subject currently enrolled in the study if he or she is affected by the amendment. The revised 
informed consent form must be used to obtain consent from any new subjects who are enrolled 
into the study after the date of the approval or favorable opinion of the protocol amendment. 
17.4. 
Subject Privacy 
The Sponsor (or Sponsor representative) or any designees affirm uphold the subjects 
confidentiality. The subject will be identified by unique code only; full names will be masked 
prior to transmission to the Sponsor. The confidentiality of the subject’s personal data shall be 
protected in accordance with appropriate laws and regulations. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
86 
04 June 2018 
If any cases are identified where the subject’s confidentiality has been breached, this must be 
rectified immediately. All subject identifiable information should be removed and the 
Sponsor notified. 
17.5. 
Protocol Amendments and Emergency Deviations 
All revisions and/or amendments to this protocol must be approved in writing by the Sponsor 
and the appropriate IRB/IEC. The Investigator will not make any changes to the conduct of the 
study or the protocol without first obtaining written approval from the Sponsor and the IRB/IEC, 
except where necessary to eliminate an apparent immediate hazard to a study subject. 
Emergency deviations or modifications may be initiated without Sponsor or IRB/IEC approval or 
favorable opinion, only in cases where the deviation or modification is necessary to eliminate or 
avoid an immediate apparent hazard to subjects. Emergency deviations or modifications must be 
reported to the Sponsor/CRO and the IRB/IEC immediately/within five business days of the 
occurrence, or in accordance with applicable regulatory requirements. 
17.6. 
Records Retention 
The Investigator/the study center must arrange for retention of study records at the study center 
for at least 15 years (or at least 25 years in the EU) from time of participation in the study or 
longer in accordance with applicable regulations and Sponsor SOPs. The Investigator/site should 
take measures to prevent accidental or premature destruction of these documents. Documents 
cannot be destroyed without written Sponsor authorization. The Sponsor will inform the 
Investigator/the study center when the destruction of documents is permitted. 
17.7. 
Inspection of Records 
In the event of an inspection, the Investigator agrees to allow representatives of the Sponsor and 
its representative and, the regulatory authorities’ access to all study records. The Investigator will 
promptly notify the Sponsor/CRO of all requests to inspect a Sunovion-/DSP-sponsored study by 
government agencies and will promptly forward a copy of all such inspection reports. 
17.8. 
Financial Disclosure 
By signing this protocol, the Investigator agrees to provide to the Sponsor prior to start of study 
accurate financial information to allow the Sponsor to submit complete and accurate certification 
and disclosure statements as required by the US FDA regulations (21 CFR Part 54). The 
Investigator further agrees to provide this information on a Financial Disclosure/Certification 
Form that is provided by the Sponsor. The Investigator will update this information if there are 
any relevant changes during the conduct of the study and for one year after completion of 
the study. 
The Investigator also consents to the transmission of this information to the Sponsor for these 
purposes. This may involve the transmission of information to countries that do not have laws 
protecting personal data. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
87 
04 June 2018 
17.9. 
Publication Policy 
Any formal presentation or publication of data collected as a direct or indirect result of the study 
will be considered a joint publication by the Investigators and the appropriate personnel of the 
Sponsor. For multicenter studies, it is mandatory that the first publication is based on all data 
obtained from all analyses as stipulated in the protocol. Investigators participating in multicenter 
studies must agree not to present data gathered individually or by a subgroup of centers before 
the full, initial publication, unless this has been agreed to by all other Investigators and by 
the Sponsor. 
The Sponsor will disclose the study results, in the form of a clinical study report synopsis, to the 
IEC and the applicable regulatory authorities within one year of the end of the study. The format 
of this synopsis and that of the clinical study report should comply with ICH E3 guidelines for 
structure and content of a clinical study report. 
Investigators participating in multicenter studies must agree not to present data gathered 
individually or by a subgroup of centers before the full, initial publication, unless this has been 
agreed to by all other Investigators and by the Sponsor. 
17.10. 
Compensation 
If subjects have any adverse event or injury directly resulting from the study medications or 
procedures, the Sponsor will appropriately compensate in accordance with applicable regulatory 
requirements. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
88 
04 June 2018 
18. 
REFERENCES 
Abbas AI, Hedlund PB, Huang XP, Huang X-P, Tran TB Meltzer HY, Roth BL. Amisulpride is 
a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology 
(Berl). 2009;205:119-28. 
American Psychiatric Association (APA) Practice guideline for the treatment of patient with 
bipolar disorder (revision). Am J Psychiatry. 2002;159(4) suppl:1-50. 
Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-6. 
Barnes TRE. The Barnes Akathisia Rating Scale – Revisited. J Psychopharmacology. 
2003;17(4):365-70. 
Diggle PJ, Heagerty P, Liang KY, and Zeger SL. The analysis of Longitudinal Data. Oxford, 
England: 2nd Edition. Oxford University Press, 2002. 
Dmitrienko A, Pulkstenis E Eds. Clinical Trial Optimization using R. CRC Press 2017. 
First MB, Williams JBW, Karg RS, Spitzer RL: Structured Clinical Interview for DSM-5—
Clinical Trials Version (SCID-5-CT); Arlington, VA, American Psychiatric Association, 2015. 
Gutierrez-Rojas L, Gurpegui M., Ayuso-Mateos JL, Gutierrez-Ariza JA, Ruiz-Veguilla M, 
Jurado D. Quality of life in bipolar disorder patients: a comparison with a general population 
sample. Bipolar Disord. 2008:10(5):625-34. 
Guy W. EDCEU Assessment Manual for Psychopharmacology – Revised (DHEW Publ No 
ADM 76-338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public 
Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH 
Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976:534-7. 
Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, et al. The long term 
natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 
2002;59:530-7. 
Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser J, et al. A prospective 
investigation of the natural history of the long-term weekly symptomatic status of bipolar II 
disorder. Arch Gen Psychiatry. 2003;60:261-9. 
Kemp DE. Managing the side effects associated with commonly used treatments for bipolar 
depression. J Affect Disord. 2014 Dec;169 Suppl 1:S34-44. 
Lecrubier Y, Boyer P, Turkanski S, Rein W, Amisulpride Study Group. Amisulpride versus 
imipramine and placebo in dysthymia and major depression. J Affect Disord. 1997;43:95-103. 
Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, Sachs G. Lurasidone monotherapy in the 
treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J 
Psychiatry. 2014 Feb;171(2):160-8. 
Merikangas KR, Akiskal HS, Angst J, Greenberg MA, Hirschfeld RM, Petukhova M, et al. 
Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity 
Survey replication. Archives of General Psychiatry. 2007;64:543-52. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
89 
04 June 2018 
Miller S, Dell’Osso B, Ketter TA. The prevalence and burden of bipolar depression. J Affect 
Disord. 2014 Dec;169 Suppl 1:S3-S11. 
Montgomery, 2002. Dopaminergic deficit and the role of amisulpride in the treatment of mood 
disorders. International Clinical Psychopharmacology. 2002;17 (suppl 4): S9-S17. 
Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement 
Scale. Hospital and Community Psychiatry. 1988;39:1172-7. 
R Core Team (2017). R: A language and environment for statistical computing. R Foundation for 
Statistical. Computing, Vienna, Austria. https://www.R-project.org/. 
Schooler NR, Chengappa KNR. Adverse effects measures. In: Handbook of Psychiatric 
Measures. Washington, D.C.: American Psychiatric Association, 2000:151-68. 
Shippee ND, Shah ND, Williams MD, Moriarty JP, Frye MA, Ziegenfuss JY. Differences in 
demographic composition and in work, social, and functional limitations among the populations 
with unipolar depression and bipolar disorder: results from a nationally representative sample. 
Health Qual Life Outcomes. 2011;9:90. 
Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatrica 
Scandinavia. Suppl 1970;212S:11-9. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
90 
04 June 2018 
19. 
INVESTIGATOR APPROVAL 
I have read the protocol SEP380-201, Version 2.00, “A Randomized, Double-Blind, 
Placebo-Controlled, Parallel-Group Study of SEP-4199 for the Treatment of Major Depressive 
Episode Associated with Bipolar I Disorder (Bipolar I Depression),” and agree that it contains all 
necessary details for conducting the study and to conduct the study in strict accordance with the 
specifications outlined herein. 
I agree that no additional procedure(s) will be added during the conduct of the study except 
through protocol amendment by Sunovion Pharmaceuticals Inc. and/or Sumitomo Dainippon 
Pharma Co., Ltd., and after documentation of IRB approval. 
Investigator Signature: ____________________________________________________ 
Print Investigator Name: __________________________________________________ 
Date: ___________________________________________ 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
91 
04 June 2018 
20. 
APPENDIX I. CARDIAC SAFETY MONITORING (ECG) 
1. Requirements for Testing 
ECG equipment and supplies will be provided by [IQVIA] and should be used for all 
in-clinic protocol ECG assessments. 
• All 12-lead ECGs will be recorded in the same manner. 
• The study center personnel must be adequately trained in performing ECGs on the 
specific ECG equipment used in this protocol that is provided by the cardiac safety 
vendor. 
• To the extent possible, the same ECG machine and personnel should be used to 
acquire a subject’s ECGs throughout the period of their participation in the study. 
• ECGs will be recorded with at least one 10-second single-lead tracing recorded from 
Lead II. 
2. Subject Restrictions and Instructions 
• Prior to ECG acquisition, the subject will have rested at least 5 minutes in the supine 
position and will remain so until the ECG is obtained. 
3. Reporting 
• It is the responsibility of the Investigator to perform a safety review of the ECG data 
for changes from previous assessments and/or emergent cardiac dysfunction, and to 
determine subjects’ eligibility or continuance in the study. 
• ECGs will be reviewed, signed and dated by the Investigator listed on the 
Form FDA 1572 (MD or DO) after each ECG collection. The same Investigator 
should review all ECG reports for a given subject whenever possible. 
• For all ECGs, a report will be provided by the cardiac safety vendor to the study 
center for review and signature. 
• The ECG tracing will be kept with subject’s source documentation and/or CRF unless 
it is specified otherwise. The original ECG and the cardiologist’s over-read will be 
retained at the study center. 
4. Data Standardization 
ECG data will be transmitted to a centralized cardiac safety vendor and centrally over-read 
and interpreted using standardized procedures. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
92 
04 June 2018 
21. 
APPENDIX II. CLINICAL LABORATORY TESTS 
Clinical Safety Panel 
HEMATOLOGY: (Differential reported as % and absolute value) 
Hemoglobin, Hematocrit, Platelet Count, RBC Count, WBC - Total Count, WBC Differential, 
(Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils) 
BLOOD CHEMISTRIES: Alanine aminotransferase (ALT), Alkaline Phosphatase (ALP), 
Aspartate aminotransferase (AST), Bicarbonate (HCO3), Bilirubin (Total, Direct, Indirect), 
Blood Urea Nitrogen (BUN), Calcium (Ca), Chloride (Cl), Creatinine, Glucose, Magnesium 
(Mg), Phosphorus (P), Potassium (K), Protein (Total), Sodium (Na), Uric Acid, Albumin 
URINALYSIS: Blood, Glucose, Ketones, Leukocyte esterase, Microscopic examination, 
Nitrites, pH, Protein 
LIPID PANEL: LDL-Cholesterol, HDL-Cholesterol, Triglycerides 
THYROID PANEL: Free T3, Free T4, Thyroid stimulating hormone (TSH) 
URINE DRUG SCREENING: Amphetamines, Barbiturates, Benzodiazepines, Cannabinoids, 
Cocaine, Cotinine, Methamphetamines, Methadone, Methylenedioxymethamphetamine 
(MDMA), Phencyclidine (PCP), Opiates, Oxycodone 
SEROLOGY PANEL: Hepatitis B Ag and Hepatitis C Ab 
RENAL FUNCTIONING: Creatinine clearance (Calculated GFR) 
OTHER TESTS: Follicle-stimulating Hormone (FSH; female subjects only), Serum Pregnancy 
(β-hCG) (female subjects only), Urine Pregnancy Test (female subjects only), HB A1C, Glucose, 
Serum Insulin, hs C-reactive Protein (CRP), Serum Prolactin 
The Investigator listed on the Form FDA 1572 (MD or DO) (or Sub-Investigator MD or DO as 
described on the delegation log) will review laboratory reports and initial and date on all pages, 
or other acceptable documentation process approved by the Sponsor. Laboratory test results will 
be reviewed by the Investigator as they become available. The Investigator must determine the 
clinical significance of all out-of-range lab values (except drug screens). Possibly drug-related or 
clinically relevant abnormal values of uncertain causality must be repeated. Any abnormal values 
that persist should be followed at the discretion of the Investigator. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
93 
04 June 2018 
22. 
APPENDIX III. BLOOD SAMPLE COLLECTION AND 
HANDLING GUIDELINES FOR PHARMACOKINETIC AND 
PLASMA PROLACTIN ASSESSMENTS 
 
Please refer to the Laboratory Investigator Manual for all collection and shipping instructions. 
 
Blood must be collected from all subjects at the time points indicated below. 
Visit No. 
Day No. 
R- and S-Amisulpride PK and Plasma Prolactin 
Blood Sample Collection Times: 
1 
-22 to -2 
Baseline prolactin 
2 
-1 
Predose 
4 
14 (± 2) 
Postdose* 
6 
42 (± 2) 
Postdose* 
7 
49 (± 2) 
Follow-up** 
* Sample will be collected after dosing is given on that day. Actual date and time will be recorded. 
** Actual date and time will be recorded. 
COLLECTION REQUIREMENTS: 
Collect 4 mL blood sample into a K2EDTA (ethylenediaminetetraacetic acid) treated 
Vacutainer® (or equivalent) tube at each time point. Invert gently 8 to 10 times to mix well. Keep 
the blood collection tube on wet ice prior to centrifugation, and centrifuge for 10 minutes at 
x 1500 g to isolate plasma within 30 minutes of blood collection. To ensure a more homogenous 
sample, all plasma samples should first be transferred to 1 tube and mixed well (by repeatedly 
aspirating and dispensing the sample into the storage tube). Split the sample with approximately 
equal volume into 2 polypropylene tubes, and label as Set-1 and Set-2. Store plasma tubes at 
approximately -70°C freezer within 1 hour until shipping to the bioanalytical lab. The date and 
time of blood collection must be recorded. 
All samples will be shipped with dry ice protection. Set-1 samples will be shipped to the 
Bioanalytical Lab for R- and S-amisulpride concentration measurements, and Set-2 samples will 
be shipped to another lab for prolactin concentration measurement. 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
94 
04 June 2018 
23. 
APPENDIX IV. PROHIBITED DRUGS KNOWN TO 
CONSISTENTLY PROLONG THE QT INTERVAL 
Generic Name 
Trade Name 
Amiodarone 
Cordarone, Pacerone 
Arsenic trioxide 
Trisenox 
Bepridil 
Vascor 
Chlorpromazine 
Thorazine 
Cisapride 
Propulsid 
Clarithromycin 
Biaxin 
Disopyramide 
Norpace 
Dofetilide 
Tikosyn 
Dolasetron Mesylate 
Anzamet 
Domperidone 
Motilium 
Droperidol 
Inapsine 
Erythromycin 
E.E.S., Erythrocin 
Gatifloxacin 
Tequin 
Halofantrine 
Halfan 
Haloperidol 
Haldol 
Ibutilide 
Corvert 
Levomethadyl 
Orlaam 
Mefloquine 
Larium 
Mesoridazine 
Serentil 
Methadone 
Dolophine, Methadose 
Moxifloxacin 
Avelox 
Pentamidine 
NebuPent 
Pentamidine 
Pentam 
Pimozide 
 
Orap 
Probucol 
Lorelco 
Procainamide 
Procan, Pronestyl 
Quinidine 
Cardioquin, Quiniglute 
Sotalol 
Betapace 
Sparfloxacin 
Zagam 
Tacrolimus 
Prograf 
Thioridazine 
Mellaril 

Protocol SEP380-201, Version 2.00 
 
SEP-4199 
Confidential and Proprietary 
95 
04 June 2018 
24. 
APPENDIX V. MINIMUM MADRS TOTAL SCORE CRITERIA 
AT BASELINE 
To be eligible for randomization, Baseline (Visit 2) MADRS total score must be ≥ 22 AND no 
more than a 25% decrease from the total score at Screening. (Refer to Table below for 
reference.) 
The following formula is to be utilized to determine the MADRS total score change at Baseline 
(Visit 2): 
MADRS total score at Screening - MADRS total score at Baseline
MADRS total score at Screening
× 100% 
 
MADRS total score 
at Screening (V1) 
MINIMUM Permissible 
MADRS total score at 
Baseline (V2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MADRS total 
score at Screening 
(V1) 
MINIMUM 
Permissible MADRS 
total score at Baseline 
(V2) 
22 
22 
42 
32 
23 
22 
43 
33 
24 
22 
44 
34 
25 
22 
45 
34 
26 
22 
46 
35 
27 
22 
47 
36 
28 
22 
48 
37 
29 
22 
49 
37 
30 
23 
50 
38 
31 
24 
51 
39 
32 
25 
52 
40 
33 
25 
53 
40 
34 
26 
54 
41 
35 
27 
55 
42 
36 
28 
56 
43 
37 
28 
57 
43 
38 
29 
58 
44 
39 
30 
59 
45 
40 
31 
60 
46 
41 
31 
- 
-